Codes for the GHO Dimension

2017-01-18

Available codes for the GHO dimension:

Label ID
Ambient air pollution attributable deaths AIR_1
Ambient air pollution attributable DALYs per 100’000 children under 5 years AIR_10
Household air pollution attributable deaths AIR_11
Household air pollution attributable deaths in children under 5 years AIR_12
Household air pollution attributable deaths per 100’000 capita AIR_13
Household air pollution attributable deaths per 100’000 children under 5 years AIR_14
Household air pollution attributable DALYs (’000) AIR_15
Household air pollution attributable DALYs (’000) in children under 5 years AIR_16
Household air pollution attributable DALYs per 100’000 capita AIR_17
Household air pollution attributable DALYs per 100’000 children under 5 years AIR_18
Population using electricity as main cooking fuel (%) AIR_19
Ambient air pollution (Annual PM10 [ug/m3]) AIR_2
Population using LPG as main cooking fuel (%) AIR_20
Population using natural gas as main cooking fuel (%) AIR_21
Population using biogas as main cooking fuel (%) AIR_22
Population using kerosene as main cooking fuel (%) AIR_23
Population using clean fuels (sum of)(%) AIR_24
Population using coal as main cooking fuel (%) AIR_25
Population using charcoal as main cooking fuel (%) AIR_26
Population using wood as main cooking fuel (%) AIR_27
Population using dung as main cooking fuel (%) AIR_28
Population using crop waste as main cooking fuel (%) AIR_29
Ambient air pollution in urban areas (Annual PM10 [μg/m3]) AIR_2_1
Ambient air pollution in urban areas (Annual PM2.5 [μg/m3]) AIR_2_2
Percentage of the total population living in cities > 100’000 inhabitants AIR_3
Population using solid fuels (sum of) (%) AIR_30
Population using others (non listed items) as main cooking fuel (%) AIR_31
Population not cooking (%) AIR_32
Missing information on cooking fuels (%) AIR_33
Total survey respondents AIR_34
Joint effects of air pollution attributable deaths AIR_35
Joint effects of air pollution attributable deaths in children under 5 years AIR_36
Joint effects of air pollution attributable deaths per 100’000 capita AIR_37
Joint effects of air pollution attributable deaths per 100’000 children under 5 years AIR_38
Percent of urban inhabitants living in cities covered by PM measurements AIR_3_1
Ambient air pollution attributable deaths in children under 5 years AIR_4
Household air pollution attributable DALYs AIR_40
Deaths attributable to ambient air pollution AIR_41
Deaths attributable to ambient air pollution (age-standardized) AIR_42
DALYs attributable to ambient air pollution AIR_43
DALYs attributable to ambient air pollution (age-standardized) AIR_44
YLLs attributable to ambient air pollution AIR_45
YLLs attributable to ambient air pollution (age-standardized) AIR_46
Deaths attributable to ambient air pollution (per 100 000) AIR_5
Deaths attributable to ambient air pollution (per 100 000, age-standardized) AIR_50
Ambient air pollution attributable deaths per 100’000 children under 5 years AIR_6
Ambient air pollution attributable DALYs (’000) AIR_7
Ambient air pollution attributable DALYs (’000) in children under 5 years AIR_8
Ambient air pollution attributable DALYs per 100’000 capita AIR_9
Government unit for treatment ATLAS_SU_0000000532
Government unit for alcohol and drugs: Location ATLAS_SU_0000000533
Government unit for alcohol: Location ATLAS_SU_0000000534
Government unit for drugs: Location ATLAS_SU_0000000535
No government unit ATLAS_SU_0000000536
Government unit for mental health/substance use: Location ATLAS_SU_0000000537
Raised blood pressure (SBP>=140 OR DBP>=90 OR on medication) (crude estimate) BP_01
Raised blood pressure (SBP>=140 OR DBP>=90 OR on medication) (age-standardized estimate) BP_02
Raised blood pressure (SBP>=140 OR DBP>=90) (crude estimate) BP_03
Raised blood pressure (SBP>=140 OR DBP>=90) (age-standardized estimate) BP_04
Mean systolic blood pressure (crude estimate) BP_05
Mean systolic blood pressure (age-standardized estimate) BP_06
Cataract surgical coverage of adults aged 50 and over (%) CATARACTSURGICAL
Effective cataract surgical coverage of adults aged 50 and over (%) CATARACTSURGICALEFFECTIVE
Poverty headcount ratio at $1.25 a day (PPP) (% of population) CCO_1
Human development index rank CCO_2
Gender inequality index rank CCO_3
Literacy rate among adults aged >= 15 years (%) CCO_WHS9_85
Climate change attributable deaths CC_1
Climate change attributable DALYs (’000) CC_2
Climate change attributable deaths per 100’000 capita CC_3
Climate change attributable DALYs per 100’000 capita CC_4
Climate change attributable deaths (’000) in children under 5 years CC_5
Climate change attributable deaths per 100’000 children under 5 years CC_6
Climate change attributable DALYs (’000) in children under 5 years CC_7
Climate change attributable DALYs per 100’000 children under 5 years CC_8
Number of reported cases of cholera CHOLERA_0000000001
Number of reported deaths from cholera CHOLERA_0000000002
Cholera case fatality rate CHOLERA_0000000003
Raised total cholesterol (>= 5.0 mmol/L) (crude estimate) CHOL_01
Raised total cholesterol (>= 5.0 mmol/L) (age-standardized estimate) CHOL_02
Mean Total Cholesterol (age-standardized estimate) CHOL_03
Mean Total Cholesterol (crude estimate) CHOL_04
Raised total cholesterol (≥ 6.2 mmol/L) (age-standardized estimate) CHOL_05
Raised total cholesterol (≥ 6.2 mmol/L) (crude estimate) CHOL_06
Number of under-five deaths (thousands) CM_01
Number of infant deaths (thousands) CM_02
Number of neonatal deaths (thousands) CM_03
Process evaluation was employed to assess implementation Camp_airtime
Formative research was conducted Camp_aud_research
Outcome evaluation was employed to assess effectiveness Camp_eval_impact
Campaign was part of a comprehensive tobacco control programme Camp_gov_prog
Campaign was pre-tested Camp_mat_tested
Campaign utilized media planning Camp_media_planning
At least one national mass media campaign ran during the survey period Camp_nat
Earned media/public relations were used to promote the campaign Camp_news
Campaign aired on television and/or radio Camp_tv_radio
Congenital syphilis number of reported cases CaseCS
Disability-adjusted life years (DALYs), children aged under 5 years (000s) DALYS04Y000
Disability-adjusted life years (DALYs) per 100 000 population DALYSPER100000
Disability-adjusted life years (DALYs) total (000s) DALYSTOTAL
Deaths, children aged under 5 years DEATHS04Y
Deaths per 100 000 population DEATHSPER100000
Deaths total DEATHSTOTAL
Total density per 100 000 population: Hospitals DEVICES00
Total density per 100 000 population: Health posts DEVICES01
Total density per 100 000 population: Health centres DEVICES02
Total density per 100 000 population: District/rural hospitals DEVICES03
Total density per 100 000 population: Provincial hospitals DEVICES04
Total density per 100 000 population: Specialized hospitals DEVICES05
Availability of national standards or recommended lists of medical devices DEVICES06
Types of lists recommending health technology for high burden diseases DEVICES07
Total density per million population: Magnetic Resonance Imaging DEVICES08
Total density per million population: Computed tomography units DEVICES09
Total density per million population: Positron Emission tomography DEVICES10
Total density per million population: Gamma camera or Nuclear medicine DEVICES11
Total density per million population: Linear Accelerator DEVICES12
Type of nomenclature system DEVICES13
Use of nomenclature system DEVICES14
Health technology (medical device) national policy DEVICES15
Unit in the Ministry of Health responsible for the management of medical devices DEVICES16
Procurement of medical devices carried out at the national level DEVICES17
Availability of national list of approved medical devices for procurement or reimbursement DEVICES18
National guidelines, policies or recommendations on the procurement of medical devices DEVICES19
Availability of technical specifications of medical devices to support procurement or donations DEVICES20
Total density per million population: Telecobalt Unit DEVICES21
Total density per million population: Radiotherapy units DEVICES22
Total density per million females aged from 50 to 69 years old: Mammography units DEVICES23
Compliance of ban on promotional discounts E10_compliance
Promotional discounts E10_promo_discounts
Non-tobacco products identified with tobacco brand names E11_brand_stretching
Compliance of ban on non-tobacco goods AND services identified with tobacco brand names E11_compliance
Brand name of non-tobacco products used for tobacco product E12_brand_sharing
Compliance of ban on brand name of non-tobacco products used for tobacco product E12_compliance
Ban on appearance of tobacco brands in TV and/or films (product placement) E13_brand_placement
Compliance of ban on appearance of tobacco brands in TV and/or films (product placement) E13_compliance
Compliance of ban on appearance of tobacco products in TV and/or films E14_compliance
Appearance of tobacco products in TV and/or films E14_prod_tv_films
Compliance of ban on sponsored events E15_compliance
Sponsored events E15_sponsored_events
Publicity of corporate social responsibility activities by tobacco companies E16_csr_promo_self
Publicity of corporate social responsibility activities by other entities E17_csr_promo_others
Tobacco companies funding or making in-kind contributions to smoking prevention media campaigns E18_csr_anti_tobacco_media
Required anti-tobacco ads for any visual entertainment media product that depicts tobacco products, use or images E19_movies_anti_tob_ads
Compliance of ban on advertising on national TV and radio E1_compliance
National television and radio E1_nat_tv_radio
Ban on tobacco vending machines E21_vending_machines
Subnational bans on tobacco advertising, promotion and sponsorship E22_subnational_exists
Subnational advertising, promotion and sponsorship bans - at least one jurisdiction has a comprehensive ban in place E23_subnat_complete_bans_exist
Ban on internet sales of tobacco products E24_internet_sales_ban
Ban on display of tobacco products at points of sale E25_ban_display_pt_of_sale
Law requires fines for violations of direct advertising bans E26_direct_ad_fines
Law requires fines for violations of indirect advertising bans E27_indirect_ad_fines
International television and radio E2_intl_tv_radio
Compliance of ban on advertising on local magazines and newspapers E3_compliance
Local magazines and newspapers E3_nat_print
International magazines and newspapers E4_intl_print
Billboard and outdoor advertising E5_billboards
Compliance of ban on advertising on billboards and outdoor advertising E5_compliance
Compliance of ban on advertising at point of sale E6_compliance
Point of sale E6_pt_of_sale
Internet E7_internet
Compliance of ban on free distribution of tobacco products in the mail or through other means E9_compliance
Free distribution in mail or through other means E9_free_distrib
Compliance with bans on direct advertising EC_direct_compliance
Compliance with bans on promotion and sponsorship EC_indirect_compliance
Electric field (kV/m) EMFLIMITELECTRIC
Electric field limit at 1800 MHz (V/m) EMFLIMITELECTRIC1800
Electric field limit at 900 MHz (V/m) EMFLIMITELECTRIC900
Electric field (kV/m) EMFLIMITELECTRICLF
Electric field limit (V/m) EMFLIMITELECTRICRADIO
Electric field (V/m) EMFLIMITELECTRICRF
Magnetic flux density (microT) EMFLIMITMAGNETIC
Power density (W/m^2) EMFLIMITPOWERDENSITY
Power density limit at 1800 MHz (W/m^2) EMFLIMITPOWERDENSITY1800
Power density limit at 900 MHz (W/m^2) EMFLIMITPOWERDENSITY900
Limit values EMFLIMITS
Power frequency (Hz) EMFPOWERFREQUENCY
Specific absorption rate (SAR) (W/kg) EMFSAR
Existence of standards EMFSTANDARD
Legislative status EMFSTATUS
Adolescent birth rate (births per 1,000 women aged 15 to 19) EQ_ADOBIRTH
Coverage of antenatal care (4 visits) EQ_ANC
Prevalence of obesity EQ_BMI30
People who identify the use of condoms as a way to avoid AIDS (%) EQ_CONDOMUSE
Contraceptive prevalence rate among women married or in union EQ_CONTRACEPTIVE
Households with dirt floor (%) EQ_DIRTFLOOR
Coverage of DTP3 immunization EQ_DTP3
Households with soap and water at a handwashing facility (%) EQ_HANDWASHING
HIV prevalence EQ_HIVPREV
Households that have a bednet for sleeping (%) EQ_HOUSENETS
Infant mortality per 1 000 live births EQ_INFANTMORT
Households with at least one ITN for sleeping (%) EQ_ITN
Children under five who slept under an ITN the previous night (%) EQ_ITNUNDER5
Knowlege about sexual transmission of AIDS EQ_KNHIV
Coverage of measles immunization EQ_MEAIMM
Population not using any sanitation facility (open defecation) (%) EQ_OPENDEFECATION
Prevalence of (moderate or severe) overweight in children EQ_OVERWEIGHT
Prevalence of overweight and obesity EQ_OVERWEIGHTADULT
Coverage of skilled birth attendance EQ_SBA
Women that slept under a bednet last night (%) EQ_SLEPTNETS
Proportion of urban residents living in a slum area EQ_SLUM
Households that use solid fuels for cooking (%) EQ_SOLIDFUELS
Prevalence of (moderate or severe) stunting in children EQ_STUNT
Prevalence of current cigarette smoking EQ_TOBACCO
Under-five mortality per 1 000 live births EQ_U5MORT
Children under five who slept under a bednet the previous night (%) EQ_U5SLEPTNETS
Prevalence of (moderate or severe) underweight in children EQ_UNDERWEIGHT
Population living in urban areas (%) EQ_URBPOP
Slum population in urban areas (% of total population) EQ_URBSLUM
Population using improved drinking-water sources (%) EQ_WATER
Households using an improved drinking-water source (%) EQ_WATERIMPROVED
Households using a piped drinking-water source (%) EQ_WATERPIPED
Households using a piped onto premises drinking-water source (%) EQ_WATERPREMISES
Enforce bans on tobacco advertising E_Group
Number of deaths GBD_0000000036
GBD - population GBD_0000000037
GBD - crude death rate GBD_0000000038
GBD - Disability-adjusted life years (DALYS) GBD_76
GBD - Years of life lost (YLL) GBD_77
GBD - Years lost due to disability (YLD) GBD_78
Age-standardized death rates (per 100 000 population) GBD_ASDR
DALY rates (per 100,000) GBD_DALYRT
Age-standardized DALYs (per 100,000) GBD_DALYRTAGE
Death rates (per 100,000) GBD_DTHRT
Incidence (in thousands) GBD_INC
Prevalence (in thousands) GBD_PREV
Disability-adjusted life years (DALYs) GHE_DALYNUM
Disability-adjusted life years (DALYs) (per 100 000 population) GHE_DALYRATE
Years of healthy life lost due to disability (YLDs) GHE_YLDNUM
Years of healthy life lost due to disability (YLDs) (per 100 000 population) GHE_YLDRATE
Years of life lost from mortality (YLLs) GHE_YLLNUM
Years of life lost from mortality (YLLs) (per 100 000 population) GHE_YLLRATE
Estimated number of people (all ages) living with HIV HIV_0000000001
Number of adults aged 15 and over living with HIV HIV_0000000002
Number of women aged 15 and over living with HIV HIV_0000000003
Number of children under 15 living with HIV HIV_0000000004
HIV prevalence rate among adults (15-49) HIV_0000000005
Number of deaths due to HIV/AIDS HIV_0000000006
Testing and counselling facilities, reported number HIV_0000000007
Testing and counselling facilities, estimated number per 100 000 adult population HIV_0000000008
Reported number of people receiving antiretroviral therapy HIV_0000000009
Reported number of people receiving antiretroviral therapy, month and year of report HIV_0000000010
Reported number of children receiving antiretroviral therapy HIV_0000000011
Reported number of children receiving antiretroviral therapy, month and year of report HIV_0000000012
Pregnant women tested for HIV, reported number HIV_0000000013
Pregnant women tested for HIV, estimated coverage (%) HIV_0000000014
Number of pregnant women living with HIV who received antiretrovirals for preventing mother-to-child transmission HIV_0000000015
Number of pregnant women living with HIV who received antiretrovirals for preventing mother-to-child transmission, reporting period HIV_0000000016
Number of people aged 15 years and over who received HIV testing and counselling, reported number HIV_0000000017
People aged 15 years and over who received HIV testing and counselling, estimated number per 1000 adult population HIV_0000000018
Number of people aged 15 years and over who received HIV testing and counselling, reporting period HIV_0000000019
Estimated percentage of pregnant women living with HIV who received antiretrovirals for preventing mother-to-child transmission HIV_0000000020
Estimated number of pregnant women living with HIV needing antiretrovirals for preventing mother-to-child transmission based on WHO methods HIV_0000000021
Estimated number of people eligible for antiretroviral therapy according to 2010 guidelines HIV_0000000022
Estimated number of children needing antiretroviral therapy based on WHO methods HIV_0000000023
Estimated antiretroviral therapy coverage among children HIV_0000000024
Testing and counselling facilities, reporting period HIV_0000000025
Number of new HIV infections HIV_0000000026
Estimated antiretroviral therapy coverage among people living with HIV (%) HIV_ARTCOVERAGE
Number of nursing personnel HRH_01
Number of physicians HRH_02
Number of midwifery personnel HRH_03
Number of pharmacists HRH_04
Number of pharmaceutical technicians/assistants HRH_05
Number of community health workers HRH_06
Number of traditional birth attendants HRH_07
Number of radiographers HRH_08
Number of other health workers HRH_09
Number of dental technicians/assistants HRH_10
Number of health management & support workers HRH_11
Number of environment and public health workers HRH_12
Number of laboratory scientists HRH_13
Number of laboratory technicians/assistants HRH_14
Number of dentists HRH_15
Number of traditional medicine practitioners HRH_16
Number of medical assistants HRH_17
Number of personal care workers HRH_18
Number of pharmaceutical personnel HRH_19
Number of laboratory health workers HRH_20
Number of dentistry personnel HRH_21
Number of community and traditional health workers HRH_22
Number of other health workers HRH_23
Number of nursing and midwifery personnel HRH_24
Pharmaceutical personnel density (per 1000 population) HRH_25
Physicians density (per 1000 population) HRH_26
Laboratory health workers density (per 1000 population) HRH_27
Dentistry personnel density (per 1000 population) HRH_28
Community and traditional health workers density (per 1000 population) HRH_29
Other health workers density (per 1000 population) HRH_30
Environmental and public health workers density (per 1000 population) HRH_31
Health management & support workers density (per 1000 population) HRH_32
Nursing and midwifery personnel density (per 1000 population) HRH_33
Biomedical engineers density (per 10 000 population) HRH_40
Number of licensed qualified surgeons actively working HRH_41
Number of licensed qualified obstetricians actively working HRH_42
Number of licensed qualified anaesthesiologists actively working HRH_43
Handwashing with soap after using the toilet (%) HWWS_1
Handwashing with soap after cleaning child’s stool (%) HWWS_2
Legislation IHR01
Coordination IHR02
Surveillance IHR03
Response IHR04
Preparedness IHR05
Risk communication IHR06
Human resources IHR07
Laboratory IHR08
Points of entry IHR09
Zoonosis IHR10
Food safety IHR11
Chemical IHR12
Radionuclear IHR13
Percentage of sites for which carbamate resistance was reported IR_CARBAMATE_EXTENT
Carbamate resistance reported for at least one site IR_CARBAMATE_PRESENCE
Number of insecticide classes to which resistance was reported IR_INSECTICIDERESISTANCE_PREV
Percentage of sites for which organochlorine resistance was reported IR_ORGANOCHLORINE_EXTENT
Organochlorine resistance reported for at least one site IR_ORGANOCHLORINE_PRESENCE
Percentage of sites for which organophosphate resistance was reported IR_ORGANOPHOSPHATE_EXTENT
Organophosphate resistance reported for at least one site IR_ORGANOPHOSPHATE_PRESENCE
Percentage of sites for which pyrethroid resistance was reported IR_PYRETHROID_EXTENT
Pyrethroid resistance reported for at least one site IR_PYRETHROID_PRESENCE
Percentage of individuals using the Internet ITU_ICT_1
Mobile-cellular telephone subscriptions per 100 inhabitants ITU_ICT_2
ICT Development Index (IDI) ITU_IDI
ICT Development Index (IDI) rank ITU_IDI_RANK
Legally binding lead controls LEADCONTROL
Name of legislation for lead controls LEADCONTROLEGISLATION
Description of legislation for lead controls LEADCONTROLEGISLATIONDESC
Percentage of the children under 15 years with blood lead levels above 5ug/dl LEAD_1
Lead attributable DALYs per 100’000 children under 5 years LEAD_10
Percentage of the children under 15 years with blood lead levels above 10ug/dl LEAD_2
Percentage of the adults (15+ years) with blood lead levels above 5ug/dl LEAD_3
Percentage of the adults (15+ years) with blood lead levels above 10ug/dl LEAD_4
Lead attributable deaths LEAD_5
Lead attributable DALYs (’000) LEAD_6
Lead attributable deaths per 100’000 capita LEAD_7
Lead attributable DALYs per 100’000 capita LEAD_8
Lead attributable DALYs (’000) in children under 5 years LEAD_9
Disability-adjusted life years (DALYs) due to leptospirosis LEPTO_DALY
Disability-adjusted life years (DALYs) (per 100 000 population) due to leptospirosis LEPTO_DALY100K
Estimated leptospirosis incidence (per 100 000 population) LEPTO_MORBIDITY
Estimated leptospirosis deaths (per 100 000 population) LEPTO_MORTALITY
Years of healthy life lost to disability (YLDs) due to leptospirosis LEPTO_YLD
Years of healthy life lost to disability (YLDs) (per 100 000 population) due to leptospirosis LEPTO_YLD100K
Years of life lost (YLLs) due to leptospirosis LEPTO_YLL
Years of life lost (YLLs) (per 100 000 population) due to leptospirosis LEPTO_YLL100K
nMx - age-specific death rate between ages x and x+n LIFE_0000000029
nqx - probability of dying between ages x and x+n LIFE_0000000030
lx - number of people left alive at age x LIFE_0000000031
ndx - number of people dying between ages x and x+n LIFE_0000000032
nLx - person-years lived between ages x and x+n LIFE_0000000033
Tx - person-years lived above age x LIFE_0000000034
ex - expectation of life at age x LIFE_0000000035
Malaria - number of reported deaths MALARIA001
Estimated number of malaria cases MALARIA002
Estimated number of malaria deaths MALARIA003
Number of under-five deaths from malaria MALARIA004
Malaria incidence per 100 000 population MALARIA005
All-cause outpatient cases MALARIA_15029
All-cause inpatient cases MALARIA_15030
All-cause inpatient deaths MALARIA_15031
Total RDT examined MALARIA_15032
Total RDT positive MALARIA_15033
Total microscopy examined MALARIA_15034
Total microscopy positive MALARIA_15035
Number of P. falciparum MALARIA_15036
Number of P. vivax MALARIA_15037
Number of mixed infections MALARIA_15040
Suspected malaria cases MALARIA_15043
Malaria outpatient cases MALARIA_15049
Malaria inpatient cases MALARIA_15056
Malaria attributed deaths MALARIA_15059
RDT Positive cases at community level MALARIA_15063
Number of reported presumed and confirmed malaria cases MALARIA_15065
ANC first attendance MALARIA_15077
IPT 1st dose MALARIA_15079
IPT 2nd dose MALARIA_15080
IPT 3rd dose MALARIA_15081
Microscopy slides/RDTs examined MALARIA_15095
Microscopy slides/RDTs positive MALARIA_15096
Total number of conventional Insecticide Treated Nets (ITNs) + LLINS sold or delivered MALARIA_15116
Total number of Long Lasting Insecticide Treated Nets (LLINs) sold or delivered MALARIA_15117
Spraying cycle MALARIA_15130
Number of households sprayed at least once MALARIA_15136
Number of households targeted for spraying MALARIA_15137
Number people targeted for protection by IRS MALARIA_15138
Number of people protected by IRS MALARIA_15139
Number of ACT only treatment doses received (public facilities and community) MALARIA_15150
Population MALARIA_15279
Government health budget (USD) MALARIA_15283
Government budget for malaria (USD) MALARIA_15284
Contributions from the Global Fund (USD) MALARIA_15287
Contributions from the Wolrdbank (USD) MALARIA_15288
European Union (USD) MALARIA_15309
Gov. expenditure on malaria (USD) MALARIA_15310
Number of health facility reports received per year (Outpatient) MALARIA_16201
Number of health facilities (Outpatient) MALARIA_16202
Number of reports expected per health facility per year (Outpatient) MALARIA_16203
Number of Admin 2 reports received per year (Outpatient) MALARIA_16205
Number of Admin 2 units (Outpatient) MALARIA_16206
Number of reports expected per Admin 2 per year (Outpatient) MALARIA_16207
RDT tested at community level MALARIA_16209
Cases at community level (presumed and confirmed) MALARIA_16210
Examined (by microscopy and RDT)(Active case detection) MALARIA_16211
Positive (by microscopy and RDT)(Active case detection) MALARIA_16212
Number of houses or structures targeted MALARIA_16221
Number of houses or structures sprayed at least once MALARIA_16222
Number distributed through mass campaign MALARIA_16223
Number distributed through ANC MALARIA_16224
Number distributed through EPI MALARIA_16225
Number distributed through other channels MALARIA_16226
Number of malaria cases treated with ACT in public facilities MALARIA_16227
Number of RDTs delivered (public facilities and community) MALARIA_16228
Number of P. falciparum (RDT test) MALARIA_16229
Number of other plamodium species (RDT test) MALARIA_16230
All-cause deaths (including malaria death) (Vital registration) MALARIA_16231
Malaria deaths (including confirmed deaths) (Vital registration) MALARIA_16232
Other (NGOs, foundations,etc) MALARIA_16233
Programme Management (PM) MALARIA_16234
Entomology and vector control (ITN, IRS, others) MALARIA_16235
Surveillance, Monitoring and Evaluation (SME) MALARIA_16236
Diagnosis and case manangement (incl. IPT) MALARIA_16237
Communications and Advocacy (CAD) MALARIA_16238
Training MALARIA_16239
Others MALARIA_16240
High endemic or risk areas ( RMI > 1) MALARIA_16252
Low endemic or epidemic-prone areas ( RMI < 1) MALARIA_16253
Malaria-free areas (no indigenous transmission) MALARIA_16254
Number of ACT only treatment doses received (public facilities only) MALARIA_16261
Total number of ACT treatment courses distributed MALARIA_16262
Number of malaria cases treated with ACT (Community level) MALARIA_16263
WHO MALARIA_16264
UNICEF MALARIA_16265
Other UN agencies MALARIA_16266
PMI MALARIA_16267
Other bilaterals MALARIA_16268
Number of health facility reports received per year (Inpatient) MALARIA_16270
Number of health facilities (Inpatient) MALARIA_16271
Number of reports expected per health facility per year (Inpatient) MALARIA_16272
Number of Admin 2 reports received per year (Inpatient) MALARIA_16273
Number of Admin 2 units (Inpatient) MALARIA_16274
Number of reports expected per Admin 2 per year (Inpatient) MALARIA_16275
Number of conventional insecticide-treated nets (ITNs) sold or delivered MALARIA_20126
Insecticide used MALARIA_20129
Total number of 1st line treatment course distributed MALARIA_20132
Household Net Possession - Percentage with at least one (Any type of mosquito net ) MALARIA_30514
Household Net Possession - Percentage with more than one (Any type of mosquito net ) MALARIA_30515
Household Net Possession - Average number of nets per household (Any type of mosquito net ) MALARIA_30516
Household Net Possession - Percentage with at least one (Ever treated mosquito net ) MALARIA_30517
Household Net Possession - Percentage with more than one (Ever treated mosquito net ) MALARIA_30518
Household Net Possession - Average number of ever treated nets per household (Ever treated mosquito net ) MALARIA_30519
Household Net Possession - Percentage with at least one (Insecticide treated mosquito nets (ITNs) ) MALARIA_30520
Household Net Possession - Percentage with more than one (Insecticide treated mosquito nets (ITNs) ) MALARIA_30521
Household Net Possession - Average number of ITNs per household (Insecticide treated mosquito nets (ITNs) ) MALARIA_30522
Household Net Possession - (Number of households ) MALARIA_30523
IPT and Anti-malarial Treatment - Percentage who took 2+ doses SP/Fansidar MALARIA_30526
Prompt Treatment - Percentage who took antimalarial drugs (Among children under age five with fever) MALARIA_30532
Prompt Treatment - Percentage who took antimalarial drugs same or next day (Among children under age five with fever) MALARIA_30533
Children with fever - Percentage of children who took drug: SP/ Fansidar MALARIA_30535
Children with fever - Percentage of children who took drug: Chloroquine MALARIA_30536
Children with fever - Percentage of children who took drug: Combination with artemisinin MALARIA_30539
Children with fever - Percentage of children who took drug the same or next day: SP/ Fansidar MALARIA_30541
Children with fever - Percentage of children who took drug the same or next day: Chloroquine MALARIA_30542
Children with fever - Percentage of children who took drug the same or next day: Combination with artemisinin MALARIA_30545
Use of mosquito nets - Percentage of under 5 who slept under any net last night MALARIA_30548
Use of mosquito nets - Percentage of under 5 who slept under an ever treated net last night MALARIA_30549
Use of mosquito nets - Percentage of under 5 who slept under an ITN last night MALARIA_30550
Use of mosquito nets - Number of children under 5 MALARIA_30555
Use of mosquito nets - Percentage of all women age 15-49 who Slept under any net last night MALARIA_30556
Use of mosquito nets - Percentage of all women age 15-49 who Slept under an ever treated net last night MALARIA_30557
Use of mosquito nets - Percentage of all women age 15-49 who Slept under an ITN last night MALARIA_30558
Use of mosquito nets - Number of pregnant women MALARIA_30559
Use of mosquito nets - Percentage of pregnant women age 15-49 who Slept under any net last night MALARIA_30560
Use of mosquito nets - Percentage of pregnant women age 15-49 who Slept under an ever treated net last night MALARIA_30561
Use of mosquito nets - Percentage of pregnant women age 15-49 who Slept under an ITN last night MALARIA_30562
Imported cases MALARIA_40105
Infant mortality rate (probability of dying between birth and age 1 per 1000 live births) MDG_0000000001
Adolescent birth rate (per 1000 women aged 15-19 years) MDG_0000000003
Contraceptive prevalence (%) MDG_0000000005
Contraceptive prevalence, among girls aged 15-19 (%) MDG_0000000005_AGE1519
Unmet need for family planning (%) MDG_0000000006
Unmet need for family planning, among girls aged 15-19 (%) MDG_0000000006_AGE1519
Under-five mortality rate (probability of dying by age 5 per 1000 live births) MDG_0000000007
Median availability of selected generic medicines (%) - Public MDG_0000000010
Median consumer price ratio of selected generic medicines - Public MDG_0000000011
Antiretroviral therapy coverage among people with advanced HIV infection (%) MDG_0000000012
Children aged <5 years sleeping under insecticide-treated nets (%) MDG_0000000013
Children aged <5 years with fever who received treatment with any antimalarial (%) MDG_0000000014
Prevalence of condom use by adults during higher-risk sex (15-49) (%) MDG_0000000015
Deaths due to malaria (per 100 000 population) MDG_0000000016
Deaths due to tuberculosis among HIV-negative people (per 100 000 population) MDG_0000000017
Deaths due to tuberculosis among HIV-positive people (per 100 000 population) MDG_0000000018
Prevalence of HIV among adults aged >=15 years (per 100 000 population) MDG_0000000019
Incidence of tuberculosis (per 100 000 population per year) MDG_0000000020
Population aged 15-24 years with comprehensive correct knowledge of HIV/AIDS (%) MDG_0000000021
Tuberculosis detection rate under DOTS (%) MDG_0000000022
Prevalence of tuberculosis (per 100 000 population) MDG_0000000023
Tuberculosis treatment success under DOTS (%) MDG_0000000024
Births attended by skilled health personnel (%) MDG_0000000025
Births attended by skilled health personnel, among girls aged 15-19 (%) MDG_0000000025_AGE1519
Maternal mortality ratio (per 100 000 live births) MDG_0000000026
Children aged <5 years stunted (%) MDG_0000000027
Population below minimum level of dietary energy consumption MDG_0000000028
Prevalence of HIV among adults aged 15 to 49 (%) MDG_0000000029
Smear-positive tuberculosis case-detection rate (%) MDG_0000000030
Smear-positive tuberculosis treatment-success rate (%) MDG_0000000031
Maternal mortality ratio (per 100 000 live births) - Country reported estimates MDG_0000000032
Antiretroviral therapy coverage among people with HIV infection eligible for ART according to 2010 guidelines (%) MDG_0000000033
Antiretroviral therapy coverage among people with advanced HIV infection (%), WHO 2006 guidelines MDG_0000000034
OOP as a % of THE MEDS
Generic MEDS0_0_0
Population MEDS1_01_01
GDP MEDS1_01_03
Gross domestic product per capita MEDS1_01_05
Life Expectancy M MEDS1_02_01
Life Expectancy F MEDS1_02_02
Infant mortality MEDS1_02_03
Under 5 Mortality MEDS1_02_04
NCD mortality rate MEDS1_02_11
CVD and Diabetes mortality rate MEDS1_02_12
Cancer mortality rate MEDS1_02_13
HIV mortality rate MEDS1_02_14
TB mortality rate MEDS1_02_15
Malaria mortality rate MEDS1_02_16
Total Pharmaceutical Expenditure (millions US$) MEDS201110200
Total Pharmaceutical Expenditure per capita (US$)rate) MEDS201120200C
Share of Total Pharmaceutical Expenditure in Total Health Expenditure (%) MEDS2011400C
Share of Public Pharmaceutical Expenditure in Total Pharmaceutical Expenditure (%) MEDS2011600C
Public Pharmaceutical Expenditure per capita (US$) MEDS201170200C
Market share of generic pharmaceuticals by value (%) MEDS2012100S
Density of pharmacists (per 10 000 population) MEDS2020200C
THE MEDS2_01_01_02
THE per capita MEDS2_01_03_02
Public Health Expenditure MEDS2_01_04_02
Public Health Expenditure as a % of Government Expenditure MEDS2_01_05
Public Health Expenditure of a % of THE MEDS2_01_06
Public Health Expenditure per capita MEDS2_01_07_02
Private Health Expenditure % of THE MEDS2_01_08
Population covered by a public health service orr insurance plan MEDS2_01_09
Population covered by private health insurance MEDS2_01_10
Total pharmaceutical expenditure MEDS2_01_11_02
Total pharmaceutical expenditure per capita MEDS2_01_12_02
Share of total pharmaceutical expenditure in gross domestic product (%) MEDS2_01_13
Share of total pharmaceutical expenditure in total health expenditure (%) MEDS2_01_14
Share of public pharmaceutical expenditures in total pharmaceutical expenditures (US$) MEDS2_01_15_02
Share of public pharmaceutical expenditures in total pharmaceutical expenditures (%) MEDS2_01_15_02_01
Private TPE MEDS2_01_18_02
Market share of generic pharmaceuticals by value (%) MEDS2_01_21
OOP as a % of Private Health Expenditure MEDS2_01_24
Premiums for private health plans as a % of private health expenditure MEDS2_01_26
Pharmacists MEDS2_02_01
Density of pharmacist (per 10.000) MEDS2_02_02
Presence of National Medicines Policy MEDS3010400
Presence of National Medicines Policy implementation plan MEDS3010700
Right of access to essential medicines MEDS3011000
For the pharmaceutical sector MEDS3011302
Presence of National Health Policy MEDS3_01_01
NHP Implementation plan exists MEDS3_01_02
Presence of national medicines policy MEDS3_01_04
Presence of national medicines policy implementation plan MEDS3_01_07
Presence of National Clinical Laboratory Policy MEDS3_01_08
NCLP implementation plan exists MEDS3_01_09
Right of access to essential medicines MEDS3_01_10
Official guidelines on medicine donations exist MEDS3_01_11
Pharmaceutical policy implementation is regularly monitored MEDS3_01_12_01
Presence of national good governance policy MEDS3_01_13
Policy to manage conflict of interest issues MEDS3_01_14
Formal code of conduct for public officials MEDS3_01_15
Whistle Blowing mechanism MEDS3_01_16
Market share of domestic manufacturers (%) MEDS4020300
Legal provision for granting patents on: Pharmaceuticals MEDS4_01_02_01
Legal provision for granting patents on: Laboratory Supplies MEDS4_01_02_02
Legal provision for granting patents on: Medical Supplies MEDS4_01_02_03
Legal provision for granting patents on: Medical Equipment MEDS4_01_02_04
TRIPS legislated through national legislation MEDS4_01_04
Trasitional period eligibility MEDS4_01_06
Compulsory Licensing MEDS4_01_07_01
Bolar exemption MEDS4_01_07_02
Parallel importing MEDS4_01_08
Legal provisions related to: Data exclusivity MEDS4_01_10
Legal provisions related to: Patent Extension MEDS4_01_11
Legal provisions for the linkage between patent status and market authorization MEDS4_01_12
Number of licensed pharmaceutical manufacturers MEDS4_02_01
Manufacturing capacity: R&D new API MEDS4_02_02_01
Manufacturing capacity: Production API MEDS4_02_02_02
Manufacturing capacity: Production formulations MEDS4_02_02_03
Manufacturing capacity: Repackaging of finished dose forms MEDS4_02_02_04
Market share of domestic manufacturers by value (%) MEDS4_02_03
Market share of domestic manufactures by volume (%) MEDS4_02_05
Existence of formal Medicines Regulatory Authority MEDS5010200
Website of the formal Medicines Regulatory Authority MEDS5010700
Market Authorization for all pharmaceutical products required MEDS5020100
Number of registered pharmaceutical products MEDS5020600
Registration Fee pharmaceutical containing New Chemical Entity MEDS5021700S
Registration Fee generic pharmaceutical product MEDS5021800S
Inspectors are allowed to inspect premises where pharmaceutical activities are performed MEDS5030200
Pharmaceutical manufacturers must comply with Good Manufacturing Practices MEDS5050200
Licensing private pharmacies obligatory MEDS5050900
National Quality Control Laboratory exists MEDS5060200
Legal provisions control promoting and advertising of prescription medicine MEDS5070100
Ban on Direct to Consumer Pharmaceutical Advertising MEDS5070300
Legal provisions exist requiring authorization for conducting Clinical Trials by the MRA MEDS5080100
Annual consumption of Morphine (mg/capita) MEDS5090300
National pharmacovigilance centre linked to the MRA exists MEDS5100400
Number of reports submitted in the last two year by the pharmacovigilance centre MEDS5100800
Legal provisions for establishing MRA MEDS5_01_01
Formal medicines regulatory authority exists MEDS5_01_02
MRA part of MoH MEDS5_01_04_01
MRA semi-autonomous MEDS5_01_04_02
Function of MRA: Market Authorization MEDS5_01_05_01
Function of MRA: Inspection MEDS5_01_05_02
Function of MRA: Import Control MEDS5_01_05_03
Function of MRA: Licensing MEDS5_01_05_04
Function of MRA: Market control MEDS5_01_05_05
Function of MRA: Quality control MEDS5_01_05_06
Function of MRA: Advertising MEDS5_01_05_07
Function of MRA: Clinical trials MEDS5_01_05_08
Function of MRA: Pharmacovigilance MEDS5_01_05_09
Medicines regulatory authority has it own website MEDS5_01_07
MRA receives external technical assistance MEDS5_01_08
MRA involved in harmonization / collaboration activities MEDS5_01_09
Assessment of medicines regulatory system conducted in last 5 years MEDS5_01_10
Funding of MRA: Government MEDS5_01_11
Funding of MRA: Fees for service MEDS5_01_12
Funding of MRA: Other funding MEDS5_01_13
Funding of MRA: Revenues derived from RA kept in RA MEDS5_01_14
RA uses computerized information management system MEDS5_01_15
Market authorization for all pharmaceutical products is required MEDS5_02_01
Mechnaisms for exceptions / waiver of registration MEDS5_02_02
Mutual recognition MEDS5_02_03
Public transparency of criteria for MA application assessment MEDS5_02_04
WHO prequalification programme information used for product registration MEDS5_02_05
Number of registered pharmaceuticals MEDS5_02_06
List of pharmaceuticals with defined periodicity required to be publicly available MEDS5_02_07
Medicines registration includes INN MEDS5_02_08
Fee required for Marketing Authorization applications MEDS5_02_09
Fee for pharmaceuticals containing new chemical entity MEDS5_02_17
Registration fee generic pharmaceutical product MEDS5_02_18
Legal provisions for the appointment of government pharmaceutical officials MEDS5_03_01
Inspectors are allowed to inspect premises where pharmaceutical activities are performed MEDS5_03_02
Inspection a pre-requisite for licensing of: Public MEDS5_03_03_01
Inspection a pre-requisite for licensing of: Private MEDS5_03_03_02
Inspection requirements the same for public and private facilities MEDS5_03_04
Local manufacturers - GMP compliance MEDS5_03_05_01
Private Wholesalers MEDS5_03_05_02
Retail distributors MEDS5_03_05_03
Public pharmacies and stores MEDS5_03_05_04
Pharmacies and dispensing points of health facilities MEDS5_03_05_05
Authorization to import medicines required MEDS5_04_01
Sampling of imported products for testing permitted MEDS5_04_02
Importation of medicines through authorized ports of entry MEDS5_04_03
Inspection of pharmaceutical products at authorized ports of entry permitted MEDS5_04_04
Licensing required for: Manufacturers MEDS5_05_01
Pharmaceutical manufacturers must comply good manufacturing practices MEDS5_05_02
Good Manufacturing Practices (GMP) published MEDS5_05_03
Licensing required for: Importers MEDS5_05_04
Licensing required for: Wholesalers MEDS5_05_05
Wholesalers and distributors to comply with Good Distribution Practices MEDS5_05_06
National Good Distribution Practice requirements published MEDS5_05_07
Pharmacists to be registered MEDS5_05_08
Licensing private pharmacies obligatory MEDS5_05_09
Licensing required for: public pharmacies MEDS5_05_10
National Good Pharmacy Practice Guidelines published MEDS5_05_11
List of all licensed pharmaceutical facilities (publication legally required) MEDS5_05_12
Legislation supports Pharmaceutical market regulation MEDS5_06_01
Quality control testing laboratory is available MEDS5_06_02
Quality control laboratory is part of medication regulatory authority MEDS5_06_02_01
Testing services contracted out by regulatory authority MEDS5_06_02_02
For quality monitoring in public sector (pharmacy stores and health facilities) MEDS5_06_04_01
For quality monitoring in private sector (retail outlets) MEDS5_06_04_02
When there are complaints / problems MEDS5_06_04_03
For product registration MEDS5_06_04_04
For public procurement prequalification MEDS5_06_04_05
For public program products prior to acceptance and/or distribution MEDS5_06_04_06
Number of quality control samples tested in past two years MEDS5_06_06
Number of samples that failed the testing in two years MEDS5_06_07
Legal provisions control promoting and advertising of prescription medicine MEDS5_07_01
Ban on direct to consumer pharmaceutical advertising MEDS5_07_03
Pre-approval for medicines advertisements and promotional materials required MEDS5_07_04
Guidelines for advertising and promotion of non-prescription medicines MEDS5_07_05
Code of conduct for advertising by MA holders exists and is publicly available MEDS5_07_06
Code of conduct applies to: Both MEDS5_07_06_01
Voluntary adherence to code MEDS5_07_06_02
Code contains formal process for complaints and sanctions MEDS5_07_06_03
Up to date list of complaints and sanctions publicly available MEDS5_07_06_04
Legal provisions exist requiring authorization for conducting clinical trials by the medical regulatory authority MEDS5_08_01
Clinical Trials require ethics committee/institutional review board approval MEDS5_08_02
Registration of clinical trials in international/national/regional registry MEDS5_08_03
Single convention on narcotic drugs, 1961 MEDS5_09_01_01
The 1972 protocol amending the single convention on narcotic drugs, 1961 MEDS5_09_01_02
Convention on psychotropic substances, 1971 MEDS5_09_01_03
United nations convention against the illicit traffic in narcotic drugs and psychotropic substances, 1988 MEDS5_09_01_04
Laws for the control of narcotic and psychotropic substances, and precursors exist MEDS5_09_02
Annual morphine consumption (mg/capita) MEDS5_09_03
PV activities legally established within MRA mandate MEDS5_10_01
MA holders required to continuously monitor safety of products and report to MRA MEDS5_10_02
Legal provisions for monitoring of ADR exist MEDS5_10_03
National pharmacovigilance center linked to the medicines regulatory authority MEDS5_10_04
Number of reports submitted in the last two years by the national pharmacovigilance center MEDS5_10_04_02
NPC publishes ADR bulletin MEDS5_10_04_03
No. of ADRs on database MEDS5_10_07
Number of reports of adverse drug reactions submitted in the last two years by the national pharmacovigilance center MEDS5_10_08
No. of ADRs submitted to Uppsala database MEDS5_10_09_01
Children <5 years receive free medicines MEDS6010102
Pregnant women receive free medicines MEDS6010103
All medicines included in the EML MEDS6010201
Social (health) fund is providing at least partial medicine coverage MEDS6010300
System in place to monitor prices of medicines MEDS6030100
Duties on imported active pharmaceutical ingredients MEDS6060100
Duties on imported finished pharmaceutical products MEDS6060200
Value Added Tax is levied on finished pharmaceuticals products MEDS6060300
Patients who cannot afford them received free medicines MEDS6_01_01_01
Children under 5 receive free medicines MEDS6_01_01_02
Pregnant women receive free medicines MEDS6_01_01_03
Elderly received free medicines MEDS6_01_01_04
All essential medicines are free MEDS6_01_02_01
Free medicines for any non communicable diseases MEDS6_01_02_02
Free medicines for Malaria MEDS6_01_02_03
Free medicines for TB MEDS6_01_02_04
Free medicines for STD MEDS6_01_02_05
Free medicines for HIV MEDS6_01_02_06
Free vaccines for EPI MEDS6_01_02_07
National or social health insurance providing at least partial medicines coverage MEDS6_01_03
Providing medicines that are on the Essential Medicines List for inpatients MEDS6_01_03_01
Providing medicines that are on the Essential Medicines List for outpatients MEDS6_01_03_02
Private health insurance schemes provide medicines coverage MEDS6_01_04
Private health insurance provides coverage for medicines which are on the EML MEDS6_01_04_01
Co-payments/ fee requirements for consultations MEDS6_02_01
Co-payments/ fee requirements for medicines MEDS6_02_02
Revenues from fees used to pay salaries of health workers MEDS6_02_03
Medicine pricing regulations MEDS6_03_01
Pricing provisions aimed at: Manufacturers MEDS6_03_01_01
Pricing provisions aimed at: Wholesalers MEDS6_03_01_02
Pricing provisions aimed at: Retailers MEDS6_03_01_03
Duties on active pharmaceutical ingredients MEDS6_06_01
Duties on finished pharmaceutical products MEDS6_06_02
Value added taxes on pharmaceutical products MEDS6_06_03
Duty rate on active pharmaceutical ingredients MEDS6_06_07
Duty rate on finished pharmaceutical products MEDS6_06_08
Value added taxes rate MEDS6_06_09
Public sector tender awards are publicly available MEDS7010400
Availability of key medicines at the Central Medical Store in percentage (%) MEDS7020900S
Public sector procurement is decentralized MEDS7_01_01_01
Public sector procurement is decentralized and centralized MEDS7_01_01_02
Public sector procurement is the reponsibility of procurement agency that is part of MOH MEDS7_01_02_01
Public sector procurement is the reponsibility of procurement agency that is semi autonomous MEDS7_01_02_02
Public sector procurement is the reponsibility of procurement agency that is autonomous MEDS7_01_02_03
A government procurement agency procures all public goods MEDS7_01_02_04
Public sector requests for tender documents are publicly available MEDS7_01_03
Public sector awards are publicly available MEDS7_01_04
Procurement is based on prequalification of suppliers MEDS7_01_05
The government supply system department has a central medical store MEDS7_02_01
There are national guidelines on Good Distribution Practices MEDS7_02_03
There is a licensing authority that issues GDP licenses MEDS7_02_04
The licensing authority accredits public distribution facilities MEDS7_02_04_01
A list of GDP certified warehouses in the public sector exists MEDS7_02_05
A list of GDP certified distributors in the public sector exists MEDS7_02_06
Availability of key medicines at the central medical store MEDS7_02_09
Legal provisions exist for licensing wholesales in private sector MEDS7_03_01
Legal provisions exist for licensing distributors in private sector MEDS7_03_02
A list of GDP certified wholsesalers in the private sector exists MEDS7_03_03
A list of GDP certified distributors in the private sector exists MEDS7_03_04
National Essential Medicine List exists MEDS8010100
Standard Treatment Guidelines for common illnesses are made by Ministry of Health MEDS8010200
National Standard Treatment Guidelines specific to paediatric conditions exist MEDS8010500
National Medicines Information Center provides information on medicines MEDS8010800
Existence of National strategy to contain antimicrobial resistance MEDS8011200
Public sector MEDS8021201
Private sector MEDS8021202
Substitution of generic equivalents at the point of dispensing in public sector facilities is allowed MEDS8030400
Substitution of generic equivalents at the point of dispensing in private sector facilities is allowed MEDS8030500
Essential medicines list exists MEDS8_01_01
Number of medicines on essential medicines list MEDS8_01_01_01
Written process for selecting medicines on the EML MEDS8_01_01_02
Written process is publicly available MEDS8_01_01_03
Mechanism to align EML and STG MEDS8_01_01_04
Standard treatment guidelines for common illnesses produced by the ministry of health MEDS8_01_02
STG specific to primary care exists MEDS8_01_03
STG specific to secondary care exists MEDS8_01_04
National standard treatment guidelines for children MEDS8_01_05
% of public health facilities with copy EML (mean) MEDS8_01_06
% of public health facilities with copy STG (mean) MEDS8_01_07
National medicines information center exists MEDS8_01_08
Public education campaigns on rational medicine use topics have been conducted in previous two years MEDS8_01_09
A survey on rational medicine use has been conducted in the previous two years MEDS8_01_10
A national committee exists to monitor and promote rational use of medicines MEDS8_01_11
National strategy to contain antimicrobial resistance exists MEDS8_01_12
AMR strategy has been updated in 2010 or later MEDS8_01_12_01
EML includes formulations specific for children MEDS8_01_14
There are explicitly documented criteria for the selection of medicines on the EML MEDS8_01_15
There is a formal committee for the selection of products on the EML MEDS8_01_16
Conflict of interest declarations are required from members of national EML committee MEDS8_01_16_01
National medicines formulary exists MEDS8_01_17
Existence of a funded national intersectoral taskforce to coordinate the promotion of appropriate use of antimicrobials MEDS8_01_18
A national reference lab has responsibility for coordinating epidemiological surveillance of AMR MEDS8_01_19
Legal provisions exist to govern the licensing and prescribing practices of prescriber MEDS8_02_01
Legal provisions exist to restrict dispensing by prescribers MEDS8_02_02
Prescribers in the private sector dispense medicine MEDS8_02_03
Regulations require hospitals to organize/develop DTCs MEDS8_02_04
More than half of referral hospital have a DTC MEDS8_02_05
More than half of general hospitals have a DTC MEDS8_02_06
More than half of regions/provinces have a DTC MEDS8_02_07
Core medical training includes: concept of EML MEDS8_02_08_01
Core medical training includes: Use for STGS MEDS8_02_08_02
Core medical training includes: Pharmacovigilance MEDS8_02_08_03
Core medical training includes: Problem based pharmacotherapy MEDS8_02_08_04
Mandatory continuing education that includes pharmaceutical issues is required for doctors MEDS8_02_09
Mandatory continuing education that includes pharmaceutical issues is required for nurses MEDS8_02_10
Mandatory continuing education that includes pharmaceutical issues is required for paramedical staff MEDS8_02_11
Public sector generic prescribing is obligatory MEDS8_02_12_01
Private sector generic prescribing is obligatory MEDS8_02_12_02
Average number of medicines prescribed per patient contact in public health facilities MEDS8_02_13
% of medicines prescribed in outpatient public health care facilities that are on the EML MEDS8_02_14
Percentage of medicines in outpatient public health care facilities that are prescribed by INN name MEDS8_02_15
Percentage of patients in outpatient public health care facilities receiving antibiotics MEDS8_02_16
Percentage of patients in outpatient public health care facilities receiving injections MEDS8_02_17
Percentage of medicines adequately labelled in public health facilities MEDS8_02_19
Diarrhoea in children treated with ORS MEDS8_02_23
Legal provisions exist to govern dispensing practices of pharmaceutical personnel MEDS8_03_01
Core pharmacist training includes: EML MEDS8_03_02_01
Core pharmacist training includes: Use of STG MEDS8_03_02_02
Core pharmacist training includes: drug information MEDS8_03_02_03
Core pharmacist training includes: clinical pharmacology MEDS8_03_02_04
Core pharmacist training includes: medicines supply management MEDS8_03_02_05
Mandatory continuing education that includes rational use of medicines is required for pharmacists MEDS8_03_03
Generic substitution permitted in public sector MEDS8_03_04
Generic substitution permitted in private sector MEDS8_03_05
Antibiotics are sometimes sold OTC without prescription MEDS8_03_06
Injectables are sometimes sold OTC without prescription MEDS8_03_07
Nurses sometimes prescribe prescription-only medicines MEDS8_03_10_01
Pharmacists sometimes prescribe prescription-only medicines MEDS8_03_10_02
Paramedics sometimes prescribe prescription-only medicines MEDS8_03_10_03
Personnel with less than one month training sometimes prescribe prescription-only medicines MEDS8_03_10_04
Number of suspected meningitis deaths reported MENING_1
Number of suspected meningitis cases reported MENING_2
Number of meningitis epidemic districts MENING_3
Mental health policy MH_1
Mental health outpatient facilities (per 100,000) MH_10
Mental health day treatment facilities (per 100,000) MH_11
Age-standardized suicide rates (per 100 000) MH_12
Beds for mental health in general hospitals (per 100,000) MH_13
Community residential facilities (per 100,000) MH_14
Beds in community residential facilities (per 100,000) MH_15
Beds in mental hospitals (per 100,000) MH_16
Mental hospitals (per 100,000) MH_17
Mental health units in general hospitals (per 100,000) MH_18
Mental hospital admissions (per 100,000) MH_19
Mental health plan MH_2
Outpatient visits (per 100,000) MH_20
Total workforce in mental health sector (per 100,000) MH_21
Occupational therapists in mental health sector (per 100,000) MH_22
Other non-specialized doctors in mental health sector (per 100,000) MH_23
Mental health units in general hospitals admissions (per 100,000) MH_24
Stand-alone policy or plan for mental health MH_25
Stand-alone mental health legislation MH_3
Government expenditures on mental health as a percentage of total government expenditures on health (%) MH_4
Government expenditures on mental hospitals as a percentage of total government expenditures on mental health (%) MH_5
Psychiatrists working in mental health sector (per 100,000) MH_6
Nurses working in mental health sector (per 100,000) MH_7
Social workers working in mental health sector (per 100,000) MH_8
Psychologists working in mental health sector (per 100,000) MH_9
Number of deaths MORT_100
Deaths per 1 000 live births MORT_200
Distribution of causes of death among children aged < 5 years (%) MORT_300
Deaths per 100 000 population MORT_400
Number of deaths MORT_500
Mortality - deaths (country) MORT_58
Mortality - population (country) MORT_59
Projection of number of deaths MORT_600
Mortality - crude death rate per 100 000 population MORT_61
Mortality - live births (country) MORT_63
Projection of deaths per 100 000 population MORT_700
Number of maternal deaths MORT_MATERNALNUM
Current smoking of cigarettes (age-standardized rate) M_Est_cig_curr
Daily smoking of cigarettes (age-standardized rate) M_Est_cig_daily
Current smoking of any tobacco product (age-standardized rate) M_Est_tob_curr
Daily smoking of any tobacco product (age-standardized rate) M_Est_tob_daily
Monitor M_Group
Adult indicator 1 rate M_def_1_prev_adult
Youth indicator 1 rate M_def_1_prev_youth
Adult indicator 1 definition M_def_1_text_adult
Youth indicator 1 definition M_def_1_text_youth
Adult indicator 2 rate M_def_2_prev_adult
Youth indicator 2 rate M_def_2_prev_youth
Adult indicator 2 definition M_def_2_text_adult
Youth indicator 2 definition M_def_2_text_youth
Adult survey age range - smokeless M_smkless_age_range_adult
Youth survey age range - smokeless M_smkless_age_range_youth
Adult smokeless tobacco use indicator definition M_smkless_def_text_adult
Youth smokeless tobacco use indicator definition M_smkless_def_text_youth
Adult smokeless tobacco use indicator rate M_smkless_prev_adult
Youth smokeless tobacco use indicator rate M_smkless_prev_youth
Name of survey of adults - smokeless M_smkless_survey_title_adult
Name of survey of youth - smokeless M_smkless_survey_title_youth
Representativeness of survey of adults - smokeless M_smkless_svy_national_adult
Representativeness of survey of youth - smokeless M_smkless_svy_national_youth
Year of survey of adults - smokeless M_smkless_svy_yr_adult
Year of survey of youth - smokeless M_smkless_svy_yr_youth
Name of survey of adults M_survey_title_adult
Name of survey of youth M_survey_title_youth
Adult survey age range M_svy_age_adult
Youth survey age range M_svy_age_youth
Representativeness of survey of adults M_svy_national_adult
Representativeness of youth survey M_svy_national_youth
Year of survey of adults M_svy_yr_adult
Year of survey of youth M_svy_yr_youth
Probability (%) of dying between exact ages 30 and 70 from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease NCDMORT3070
BMI >= 25 (age-standardized estimate) NCD_BMI_25A
BMI >= 25 (crude estimate) NCD_BMI_25C
BMI >= 30 (age-standardized estimate) NCD_BMI_30A
BMI >= 30 (crude estimate) NCD_BMI_30C
Mean BMI (kg/m2) (age-standardized estimate) NCD_BMI_MEAN
Mean BMI (kg/m2) (crude estimate) NCD_BMI_MEANC
Cancers, deaths per 100,000 (age-standardized estimate) NCD_CA
Cardiovascular diseases and diabetes, deaths per 100,000 (age-standardized estimate) NCD_CARDIO
General availability of ACE inhibitors in the public health sector NCD_CCS_ACE
General availability of acetic acid visualization at the primary health care level NCD_CCS_AceticAcid
Existence of operational policy/strategy/action plan to reduce the harmful use of alcohol NCD_CCS_AlcPlan
General availability of aspirin (100 mg) in the public health sector NCD_CCS_Aspirin
General availability of beta blockers in the public health sector NCD_CCS_BetaBlkrs
General availability of colon cancer screening at the primary health care level NCD_CCS_BowelCancer
General availability of breast cancer screening (by palpation or mammogram) at the primary health care level NCD_CCS_BreastCancer
General availability of bronchodilators in the public health sector NCD_CCS_Bronchodilators
General availability of CC blockers in the public health sector NCD_CCS_CCBlkrs
Existence of operational policy/strategy/action plan for chronic respiratory diseases NCD_CCS_CRDPlan
Existence of operational policy/strategy/action plan for cardiovascular diseases NCD_CCS_CVDPlan
Existence of operational policy/strategy/action plan for cancer NCD_CCS_CancerPlan
Existence and scope of cancer registry NCD_CCS_CancerReg
Existence of population-based cancer registry NCD_CCS_CancerRegNational
General availability of cervical cytology at the primary health care level NCD_CCS_CervCy
General availability of chemotherapy in the public health system NCD_CCS_Chemo
General availability of total cholesterol measurement at the primary health care level NCD_CCS_CholMsmt
Existence of partnerships/collaborations for implementing key activities related to NCDs NCD_CCS_Collab
Availability and stage of implementation of guidelines/protocols/standards for the management of diabetes NCD_CCS_DiabGuide
Existence of operational policy/strategy/action plan for diabetes NCD_CCS_DiabPlan
Existence of a diabetes registry NCD_CCS_DiabetesReg
General availability of diabetes testing (by blood glucose measurement, OGTT, or HbA1c) at the primary health care level NCD_CCS_DiabetesTest
Existence of operational policy/strategy/action plan to reduce unhealthy diet related to NCDs NCD_CCS_DietPlan
Earmarking of taxes from fiscal interventions to influence behaviour change used to fund health promotion programmes or a health promotion foundation NCD_CCS_Earmarking
General availability of electrocardiogram at the primary health care level NCD_CCS_Electrocard
General availability of glibenclamide in the public health sector NCD_CCS_Gliben
General availability of diabetes testing (by HbA1c) at the primary health care level NCD_CCS_HbA1c
General availability of hydrocortisone injections in the public health sector NCD_CCS_Hydrocort
Availability and stage of implementation of guidelines/protocols/standards for the management of raised blood pressure / hypertension NCD_CCS_HypGuide
General availability of insulin in the public health sector NCD_CCS_Insulin
General availability of ipratropium bromide in the public health sector NCD_CCS_Ipratro
General availability of metformin in the public health sector NCD_CCS_Metformin
Existence of any policies on marketing of foods to children NCD_CCS_Mkting
Existence of a national multisectoral commission, agency or mechanism for NCDs NCD_CCS_MultisecComm
Existence of at least one operational multisectoral national policy, strategy or action plan that integrates several noncommunicable diseases and shared risk factors in conformity with the global/regional noncommunicable disease action plans 2013?2020 NCD_CCS_MultisecNCDPlan
Existence of evidence-based national guidelines/protocols/standards for the management of major NCDs through a primary care approach NCD_CCS_NCDGuide
Existence of a set of national NCD indicators and has set time-bound national targets for these indicators NCD_CCS_NCDIndicators
Existence of Unit, Branch, or Dept. in Ministry of Health with responsibility for NCDs NCD_CCS_NCDUnit
Existence of an Operational Unit, Branch, or Dept. in Ministry of Health with responsibility for NCDs NCD_CCS_NCDUnit_Operational
General availability of nicotine replacement therapy in the public health sector NCD_CCS_Nicotine
General availability of oral morphine in the public health sector NCD_CCS_OralMorph
Existence of operational policy/strategy/action plan to reduce physical inactivity NCD_CCS_PAPlan
Has a STEPS survey or a comprehensive health examination survey every 5 years NCD_CCS_PM3_Surv
General availability of prednisolone tabs in the public health sector NCD_CCS_Prednis
Existence of risk factor surveillance for selected risk factors (harmful alcohol use, diet, physical inactivity, and tobacco use) NCD_CCS_RFSurv
General availability of radiotherapy in the public health system NCD_CCS_RadioTherapy
General availability of renal replacement therapy (by dialysis or transplantation) in the public health system NCD_CCS_RenalTherapy
General availability of retinal photocoagulation in the public health system NCD_CCS_RetinalPho
General availability of salbutamol in the public health sector NCD_CCS_Salb
Existence of any policies to reduce population salt consumption NCD_CCS_SaltPol
Existence of national policies on saturated fatty acids / trans-fats NCD_CCS_SatFat
General availability of peak flow measurement spirometry at the primary health care level NCD_CCS_Spirom
General availability of statins in the public health sector NCD_CCS_Statins
General availability of steroid inhalers in the public health sector NCD_CCS_Steroid
Existence of an NCD surveillance and monitoring system in place to enable reporting against the nine global NCD targets NCD_CCS_SurvMonRep9NCD
General availability of tamoxifen in the public health sector NCD_CCS_Tamox
Implementation of fiscal interventions to influence behaviour change NCD_CCS_Taxes
General availability of thiazide diuretics in the public health sector NCD_CCS_Thiazide
Existence of operational policy/strategy/action plan to decrease tobacco use NCD_CCS_TobPlan
General availability of urine testing for albumin NCD_CCS_UrineAlbumin
General availability of beta blockers in the public health sector NCD_CCS_betablockers
Existence of national screening program for breast cancer NCD_CCS_breastcancerscreening
Most widely used screening method in national cervical cancer screening program NCD_CCS_cervicalcancermethod
Coverage of national cervical cancer screening program (%) NCD_CCS_cervicalcancerpgmcvg
Type of national cervical cancer screening program NCD_CCS_cervicalcancerpgmtype
Existence of national screening program for cervical cancer NCD_CCS_cervicalcancerscreening
General availability of coronary bypass or stenting in the public health system NCD_CCS_coronary
General availability of diabetes testing (by blood glucose measurement, OGTT) at the primary health care level NCD_CCS_diabtest
General availability of dialysis in the public health system NCD_CCS_dialysis
Implementation of diet and/or physical activity public awareness program NCD_CCS_dietpaaware
Existence of national HPV vaccination programme NCD_CCS_hpv
Existence of an operational, multisectoral national NCD policy, strategy or action plan that integrates several NCDs and their risk factors NCD_CCS_integNCDplan
General availability of palliative care in community or home-based care in the public health system NCD_CCS_palliative_home
General availability of palliative care in primary health care in the public health system NCD_CCS_palliative_prim
General availability of retinal photocoagulation in the public health system NCD_CCS_photocoag
General availability of renal replacement by transplantation in the public health system NCD_CCS_renaltrans
Provision for secondary prevention of rheumatic fever and rheumatic heart disease in more than 50% of public sector health facilities NCD_CCS_rheum
Availability of cardiovascular risk stratification in 50% or more primary health care facilities NCD_CCS_riskstrat
Provision for care of acute stroke and rehabilitation in more than 50% of public sector health facilities NCD_CCS_stroke
General availability of sulphonylurea(s) in the public health sector NCD_CCS_sulphonylurea
General availability of thrombolytic therapy in the public health system NCD_CCS_thrombolytic
Chronic respiratory diseases, deaths per 100,000 (age-standardized estimate) NCD_CHRON
All NCDs, deaths per 100,000 (age-standardized estimate) NCD_DTH_PER
Total NCD Deaths NCD_DTH_TOT
Mean fasting blood glucose (mmol/l) (age-standardized estimate) NCD_GLUC_01
Mean fasting blood glucose (mmol/l) (crude estimate) NCD_GLUC_02
Raised fasting blood glucose (>= 7.0 mmol/L or on medication) (crude estimate) NCD_GLUC_03
Raised fasting blood glucose (>=7.0 mmol/L or on medication)(age-standardized estimate) NCD_GLUC_04
Insufficiently active (age-standardized estimate) NCD_PAA
Insufficiently active (crude estimate) NCD_PAC
Insufficiently active (crude estimate) NCD_PAC_ADO
NCD deaths under age 60 (percent of all NCD deaths) NCD_UNDER60
NCD deaths under age 70 (percent of all NCD deaths) NCD_UNDER70
Basis for NHA estimate NHABASIS
General government expenditure on health as percentage of gross domestic product NHAGGHEGDP
Out-of-Pocket expenditure on health as percentage of total health expenditure?? NHAOOPSTHE
Prepaid plans as percentage of total health expenditure? NHAPREPAIDTHE
Number of full-time equivalent staff in national agency NTCP_FTE
National agency for tobacco control exists NTCP_agcy
Budget year NTCP_budget_year
Reported currency NTCP_curr
Annual budget for tobacco control in currency reported NTCP_govt_exp
Government objectives on tobacco control exist NTCP_govt_obj
Budget year NTCP_usd
Number of new reported cases of Buruli ulcer NTD_1
Dracunculiasis certification status of countries at the beginning of the year NTD_2
Year country was certified NTD_2_YEAR_CERTIFIED
Annual incidence of dracunculiasis cases NTD_3
Number of new reported cases of human African trypanosomiasis (T.b. gambiense) NTD_4
Number of new reported cases of human African trypanosomiasis (T.b. rhodesiense) NTD_5
Status of elimination of trachoma as a public health problem NTD_6
Population in areas that warrant treatment with antibiotics, facial cleanliness and environmental improvement for elimination of trachoma as a public health problem NTD_7
Number of people who received treatment with antibiotics for trachoma NTD_8
Number of cases of bejel reported NTD_BEJELNUM
Status of bejel endemicity NTD_BEJELSTATUS
Dracunculiasis cases NTD_DRACASES
Status of endemicity of cutaneous leishmaniasis NTD_LEISHCEND
Number of cases of cutaneous leishmaniasis reported NTD_LEISHCNUM
Number of imported cases of cutaneous leishmaniasis reported NTD_LEISHCNUM_IM
Status of endemicity of visceral leishmaniasis NTD_LEISHVEND
Number of cases of visceral leishmaniasis reported NTD_LEISHVNUM
Number of imported cases of visceral leishmaniasis reported NTD_LEISHVNUM_IM
Estimated number of individuals in the country requiring preventive chemotherapy for onchocerciasis NTD_ONCHEMO
Status of endemicity of onchocerciasis NTD_ONCHSTATUS
Reported number of individuals treated for onchocerciasis NTD_ONCTREAT
Number of cases of pinta reported NTD_PINTANUM
Status of pinta endemicity NTD_PINTASTATUS
Reported number of human rabies deaths NTD_RAB2
Number of people operated for trachomatous trichiasis NTD_TRA5
Status of yaws endemicity NTD_YAWSEND
Number of cases of yaws reported NTD_YAWSNUM
Overweight numbers (in millions) NUTOVERWEIGHTNUM
Overweight prevalence NUTOVERWEIGHTPREV
Prevalence of adults aged ≥ 15 years who are moderately and severely thin (BMI <17.0) NUTRITION_0
Prevalence of adults aged ≥ 15 years who are severely thin (BMI <16.0) NUTRITION_1
Prevalence of adults aged ≥ 15 years who are mildly thin (BMI 17.0-18.49) NUTRITION_2
Minimum acceptable diet (%) NUTRITION_2005
Minimum dietary diversity (%) NUTRITION_2006
Minimum meal frequency (%) NUTRITION_2007
Prevalence of adults aged ≥ 15 years who are moderately thin (BMI 16.0-16.99) NUTRITION_3
Children aged <5 years wasted for age (%) NUTRITION_564
Prevalence of adults aged ≥ 15 years who are pre-obese (%) (BMI 25.0-29.99) NUTRITION_565
Prevalence of adults aged ≥ 15 years who are overweight (%) (BMI ? 25.0) NUTRITION_566
Prevalence of adults aged ≥ 15 years who are in normal range (%) (BMI 18.5-24.99) NUTRITION_567
Prevalence of adults aged ≥ 15 years who are underweight (%) (BMI <18.5) NUTRITION_568
Continued breastfeeding at 1 year (%) NUTRITION_569
Early initiation of breastfeeding (%) NUTRITION_570
Exclusive breastfeeding under 4 months (%) NUTRITION_571
Continued breastfeeding at 2 years (%) NUTRITION_572
Children ever breastfed (%) NUTRITION_573
Duration of any breastfeeding NUTRITION_574
Duration of exclusive breastfeeding NUTRITION_575
Introduction of solid, semi-solid or soft foods and breast milk (%) NUTRITION_576
Bottle feeding rate 0-11.9 months (%) NUTRITION_577
Bottle feeding rate 0-23.9 months (%) NUTRITION_578
Exclusive breastfeeding under 6 months (%) NUTRITION_579
Severe wasting numbers (in millions) NUTSEVWASTINGNUM
Severe wasting prevalence NUTSEVWASTINGPREV
Stunting numbers (in millions) NUTSTUNTINGNUM
Stunting prevalence NUTSTUNTINGPREV
Underweight numbers (in millions) NUTUNDERWEIGHTNUM
Underweight prevalence NUTUNDERWEIGHTPREV
Wasting numbers (in millions) NUTWASTINGNUM
Wasting prevalence NUTWASTINGPREV
Decayed, missing, or filled teeth OA_DMFT
Occupational risk factors attributable deaths OCC_1
Occupational carcinogens attributable DALYs (’000) OCC_10
Occupational carcinogens attributable deaths per 100’000 capita OCC_11
Occupational carcinogens attributable DALYs per 100’000 capita OCC_12
Occupational noise attributable DALYs (’000) OCC_13
Occupational noise attributable DALYs per 100’000 capita OCC_14
Occupational ergonomic stressors attributable deaths OCC_15
Occupational ergonomic stressors attributable DALYs (’000) OCC_16
Occupational ergonomic stressors attributable deaths per 100’000 capita OCC_17
Occupational ergonomic stressors attributable DALYs per 100’000 capita OCC_18
Occupational injuries attributable deaths OCC_19
Occupational risk factors attributable DALYs (’000) OCC_2
Occupational injuries attributable DALYs (’000) OCC_20
Occupational injuries attributable deaths per 100’000 capita OCC_21
Occupational injuries attributable DALYs per 100’000 capita OCC_22
Occupational risk factors attributable deaths per 100’000 capita OCC_3
Occupational risk factors attributable DALYs per 100’000 capita OCC_4
Occupational airborne particulates attributable deaths OCC_5
Occupational airborne particulates attributable DALYs (’000) OCC_6
Occupational airborne particulates attributable deaths per 100’000 capita OCC_7
Occupational airborne particulates attributable DALYs per 100’000 capita OCC_8
Occupational carcinogens attributable deaths OCC_9
Donor commitments (Million, constant 2009 US$) ODA_1
Commitments to recipient countries (Million, constant 2009 US$) ODA_2
Donor disbursements (Million, constant 2009 US$) ODA_3
Disbursements to recipient countries (Million, constant 2009 US$) ODA_4
Kidney transplants (absolute number) ORGANKIDNEYNUM
Kidney transplants (per million) ORGANKIDNEYRATE
Liver transplants (absolute number) ORGANLIVERNUM
Liver transplants (per million) ORGANLIVERRATE
Population (millions) ORGANPOP
Total actual deceased donors (absolute number) ORGANTOTALDECNUM
Total actual deceased donors (per million) ORGANTOTALDECRATE
Total organs transplanted (absolute number) ORGANTOTALNUM
Total organs transplanted (per million) ORGANTOTALRATE
Treatment for tobacco dependence available in the community O_Avail_community
Treatment for tobacco dependence available in health clinics or other primary care facilities O_Avail_hlthSPACEclin
Treatment for tobacco dependence available in health clinics or other primary care facilities O_Avail_hlth_clin
Treatment for tobacco dependence available in hospitals O_Avail_hosp
Treatment for tobacco dependence available in offices of health professionals O_Avail_off_hlth_prof
Treatment for tobacco dependence available in other settings O_Avail_other
Bupropion - cost covered O_Bup_ins
Bupropion - legally sold O_Bup_sold
Bupropion - place available O_Bup_where
Offer help to quit tobacco use O_Group
Treatment for tobacco dependence in the community cost covered O_Ins_community
Treatment for tobacco dependence in health clinics or other primary care facilities cost covered O_Ins_hlth_clin
Treatment for tobacco dependence in hospitals cost covered O_Ins_hosp
Treatment for tobacco dependence in offices of health professionals cost covered O_Ins_off_hlth_prof
Treatment for tobacco dependence in other settings cost covered O_Ins_other
Nicotine replacement therapy on the Essential Medicines List O_NRT_EML
Nicotine replacement therapy - cost covered O_NRT_ins
Nicotine replacement therapy - legally sold O_NRT_sold
Nicotine replacement therapy - place available O_NRT_where
Access to a toll-free quit line O_Quitline
Varenicline - cost covered O_Varen_ins
Varenicline - legally sold O_Varen_sold
Varenicline - place available O_Varen_where
Subnational smoke-free legislation authority exists P10_subnat_auth_exists
Fines for violations P11_fines_any
Fines on the establishment P12_fines_establishment
Fines on the patron P13_fines_smoker
Dedicated funds for enforcement P14_funds_for_enforce
Citizen complaints and investigations P15_complaints
Comprehensive bans in place subnationally P16_subnat_complete_bans_exist
Compliance of ban on smoking in HEALTH-CARE FACILITIES P1_compliance
Health-care facilities (national legislation) P1_healthcare
Compliance of ban on smoking in EDUCATIONAL FACILITIES EXCEPT UNIVERSITIES P2_compliance
Education facilities except universities (national legislation) P2_education
Compliance of ban on smoking in UNIVERSITIES P3_compliance
Universities (national legislation) P3_universities
Compliance of ban on smoking in GOVERNMENT FACILITIES P4_compliance
Government facilities (national legislation) P4_govt
Compliance of ban on smoking in INDOOR OFFICES P5_compliance
Indoor offices (national legislation) P5_indoor_off
Compliance of ban on smoking in RESTAURANTS P6_compliance
Restaurants (national legislation) P6_restaurants
Compliance of ban on smoking in PUBS AND BARS P7_compliance
Pubs and bars (national legislation) P7_pubs
Compliance of ban on smoking in PUBLIC TRANSPORT P8_compliance
Public transport (national legislation) P8_pub_transp
All other indoor public places (national legislation) P9_all_other
Compliance with regulations on smoke-free environments (national legislation) PC_sfe_compliance
Prevalence of anaemia in women aged 15-49 (%) PREVANEMIA
Protect from tobacco smoke P_Group
Number of places smoke-free (national legislation) P_count_places_sf
Comprehensive bans in place subnationally P_subnat_complete_ban_exists
Antenatal care attendees who were positive for syphilis (%) PercposANC
Men who have sex with men (MSM) with active syphilis (%) PercposMSM
Sex workers with active syphilis (%) PercposSW
Antenatal care (ANC) attendees tested for syphilis at first ANC visit (%) PerctestedANC
Antenatal care attendees positive for syphilis who received treatment (%) PerctreatedANC
Intimate partner violence prevalence among ever partnered women (%) RHR_IPV
Non-partner sexual violence prevalence (%) RHR_NPSV
Point prevalence (%), alcohol use disorders, 15+ years RSUD_1
National survey on substance use among children and adolescents RSUD_10
Data on substance use disorders disseminated in national annual reports RSUD_11
Substance use policy at the national level RSUD_12
Substance use policy at the national level, level of integration RSUD_13
Policy documents on the pharmacological treatment of substance use disorders RSUD_14
Guidelines on the pharmacological treatment of substance use disorders RSUD_15
Legislative provision for treatment and rehabilitation of substance use disorders RSUD_16
Legislative provision for compulsory treatment RSUD_17
Drug courts RSUD_18
Programmes diverting clients from the justice system towards treatment RSUD_19
Point prevalence (%), drug use disorders, 15+ years RSUD_2
Confidentiality of health records on substance use disorders protected by law RSUD_20
Government unit for substance use disorder treatment RSUD_21
Budget line for substance use disorder treatment RSUD_22
Financing method for substance use disorder treatment RSUD_23
Treatment services for alcohol use disorders, free of charge RSUD_24
Treatment services for drug use disorders, free of charge RSUD_25
Governement benefits for persons with substance use disorders RSUD_26
Government benefits for alcohol use disorders, subsidy or disability pension RSUD_27
Government benefits for drug use disorders, subsidy or disability pension RSUD_28
Sector for inpatient detoxification of alcohol use disorders RSUD_29
Age-standardized death rates, alcohol and drug use disorders, per 100 000 RSUD_3
Sector for inpatient treatment of alcohol dependence RSUD_30
Sector for outpatient treatment of alcohol dependence RSUD_31
Sector for the treatment of alcohol-induced psychoses and other alcohol-induced psychiatric conditions RSUD_32
Sector for residential long-term rehabilitation of alcohol use disorders RSUD_33
Sector for inpatient detoxification of drug use disorders RSUD_34
Sector for inpatient treatment of drug dependence RSUD_35
Sector for outpatient treatment of drug dependence RSUD_36
Sector for substitution maintenance therapy of opioid dependence RSUD_37
Sector for residential long-term rehabilitation of drug use disorders RSUD_38
Treatment system for substance use disorders RSUD_39
Age-standardized death rates, drug use disorders, per 100 000 RSUD_4
Treatment setting for substance use disorders, most common RSUD_40
Specialized treatment services for drug use disoders and HIV/AIDS RSUD_41
Specialized treatment services for substance use disorders and TB RSUD_42
Open access services for substance use disorders RSUD_43
Treatment slots for alcohol and drug use disorders, outpatient, per 10 000 RSUD_44
Beds for the treatment of substance use disorders, per 100 000 RSUD_45
Length of stay for inpatient detoxification, days RSUD_46
Length of stay for inpatient short-term treatment, days RSUD_47
Length of stay for inpatient long-term residential treatment, days RSUD_48
Opioid agonist pharmacotherapy for the treatment of opioid dependence (detoxification or maintenance) RSUD_49
Age-standardized DALYs, alcohol and drug use disorders, per 100 000 RSUD_5
Timeframe of opioid agonist treatment RSUD_50
Methadone used for the treatment of opioid dependence RSUD_51
Methadone used for detoxification or maintenance RSUD_52
Methadone formulation used for the treatment of opiod dependence RSUD_53
Buprenorphine used for the treatment of opioid dependence RSUD_54
Buprenorphine used for detoxification or maintenance RSUD_55
Buprenorphine/naloxone used for the treatment of opioid dependence RSUD_56
Buprenorphine/naloxone used for detoxification or maintenance RSUD_57
Methadone provision in clinical and community-based settings RSUD_58
Buprenorphine provision in clinical and community-based settings RSUD_59
Age-standardized DALYs, drug use disorders, per 100 000 RSUD_6
Buprenorphine/naloxone provision in clinical and community-based settings RSUD_60
Supervision requirements for methadone administration RSUD_61
Supervision requirements for buprenorphine administration RSUD_62
Supervision requirements for buprenorphine/naloxone administration RSUD_63
Prescription requirements for methadone RSUD_64
Prescription requirements for buprenorphine RSUD_65
Prescription requirements for buprenorphine/naloxone RSUD_66
Commencement of treatment with opioid agonists RSUD_67
Pharmacotherapy used for the management of alcohol withdrawal RSUD_68
Pharmacotherapy used for the management of benzodiazepine withdrawal RSUD_69
Psychoactive substance causing entry into treatment RSUD_7
Pharmacotherapy used for the management of cannabis withdrawal RSUD_70
Essential list of medicines RSUD_71
Essential list of medicines, pharmacotherapy for substance use disorders RSUD_72
Government unit for substance use disorder prevention RSUD_73
Budget line for substance use disorder prevention RSUD_74
Funding method for substance use disorder prevention RSUD_75
Prevention activities for substance use disorders, main focus RSUD_76
Programmes for the prevention of substance use disorders for special populations RSUD_77
Screening and brief interventions for substance use and substance use disorders RSUD_78
Harm reduction programmes for IDUs RSUD_79
Epidemiological data collection system for substance use disorders RSUD_8
Health professionals mostly involved in treatment of substance use disorders RSUD_80
Clinical supervision of health care staff RSUD_81
Standards of care for health professionals RSUD_82
Standards of care for health professionals, maintenance RSUD_83
Standards of care for health professionals, human rights RSUD_84
NGOs for alcohol use disorders RSUD_85
NGOs for drug use disorders RSUD_86
Self-help groups for substance use disorders RSUD_87
Groups and agencies for the prevention of substance use disorders RSUD_88
Opioid agonist pharmacotherapy for the treatment of opioid dependence (maintenance) RSUD_89
Service delivery data collection system for substance use disorders RSUD_9
Population RS_1845
Income level RS_193
Number of registered vehicles RS_194
Estimated number of road traffic deaths RS_196
Estimated road traffic death rate (per 100 000 population) RS_198
Existence of a national drink-driving law RS_204
Definition of drink-driving by BAC RS_205
Blood Alcohol Concentration (BAC) limit for drivers RS_207
Attribution of road traffic deaths to alcohol (%) RS_208
Existence of a national seat-belt law RS_209
Applicability of seat-belt law to all occupants RS_210
Seat-belt wearing rate (%) RS_212
Existence of a national child-restraint law RS_213
Existence of national speed limits RS_214
Adaptation of national speed limit at a local level RS_215
Specification of national speed law by vehicle type RS_216
Maximum speed limits RS_217
Existence of a national motorcycle helmet law RS_218
Applicability of national motorcycle helmet law to all occupants RS_219
Applicability of national motorcycle helmet law to all road types RS_221
Applicability of national motorcycle helmet law to all engine types RS_222
Requirement of motorcycle helmet use to adhere to standard RS_223
Law requires helmet to be fastened RS_223_BIS
Motorcycle helmet wearing rate (%) RS_224
Existence of a road safety lead agency RS_225
Existence of a national road safety strategy RS_228
Availability of funding for national road safety strategy RS_229
Existence of a national policy on walking and cycling RS_231
Existence of a national policy on public transport RS_232
Existence of road safety audit for all new roads RS_233
Existence of road safety audit for existing roads RS_234
Type of driving tests for new drivers RS_235
Existence of mandatory vehicle insurance RS_236
Existence of a formal pre-hospital care system RS_237
Existence of a universal access telephone number for pre-hospital care RS_238
Reported % of seriously injured patients transported by ambulance RS_239
Training in medical emergency - available for doctors RS_240
Training in medical emergency - available for nurses RS_241
Vehicle standards RS_242
Distribution of road traffic deaths by type of road user (%) RS_246
Gross national income per capita (Atlas method) RS_576
Average - taxes as a % of cigarette price - ad valorem excise R_Ad_val_average
Most sold brand of cigarettes - taxes as a % of price - ad valorem excise R_Ad_val_estimate
Average - cigarette currency R_Curr_average
Cheapest brand of cigarettes - currency reported R_Curr_lowest_cost
Most sold brand of cigarettes - currency reported R_Curr_mp
Premium brand of cigarettes - currency reported R_Curr_premium_cost
Raise taxes on tobacco R_Group
Average - taxes as a % of cigarette price - other taxes R_Other_average
Most sold brand of cigarettes - taxes as a % of price - other taxes R_Other_estimate
Average - cigarette price in currency R_Price_average_curr
Average - cigarette price in international dollars R_Price_average_ppp
Average - cigarette price in US$ at official exchange rates R_Price_average_usd
Cheapest brand of cigarettes - price in currency reported R_Price_lowest_estimate
Cheapest brand of cigarettes - price in international dollars R_Price_lowest_ppp
Cheapest brand of cigarettes - price in US$ at official exchange rates R_Price_lowest_usd
Most sold brand of cigarettes - price in currency reported R_Price_mp_estimate
Most sold brand of cigarettes - price in international dollars R_Price_mp_ppp
Most sold brand of cigarettes - price in US$ at official exchange rates R_Price_mp_usd
Premium brand of cigarettes - price in currency reported R_Price_premium_estimate
Premium brand of cigarettes - price in international dollars R_Price_premium_ppp
Premium brand of cigarettes - price in US$ at official exchange rates R_Price_premium_usd
Average - taxes as a % of cigarette price - specific excise R_Sp_excise_average
Most sold brand of cigarettes - taxes as a % of price - specific excise R_Sp_excise_estimate
Average - taxes as a % of cigarette price - value added tax R_VAT_average
Most sold brand of cigarettes - taxes as a % of price - value added tax R_VAT_estimate
Tax administration: If duty free imports are limited, duty free allowance (number of cigarette sticks) R_admin_duty_free_allowance
Tax administration: Bans or limits on duty free imports by travellers R_admin_duty_free_limited
Tax administration: Tax stamps applied on tobacco products R_admin_tax_stamps
Affordability: % of GDP per capita required to purchase 100 packs of most sold brand (the higher the %, the less affordable) R_afford_gdp
Affordability: Cigarettes are less affordable in 2014 compared to 2008 R_afford_less
Affordability: Price dispersion: share of cheapest brand price in premium brand price (the higher the % the smaller the gap) R_afford_price_dispersion
Affordability: Specific tax component automatically adjusted for inflation (or other) R_afford_tax_auto_adjust
Tobacco excises increased over the survey period R_excise_incr
Tax structure: Minimum specific tax applied in ad valorem or mixed excise regime R_excise_min_specific
Tax structure: Excise tax proportion of price R_excise_proportion
Tax structure: Retail price used as base of ad valorem component in ad valorem or mixed excise regime (or retail price exclusive of VAT) R_excise_retail_price_base
Tax structure: Greater reliance on specific tax in mixed excise regime R_excise_specific_reliance
Tax structure: Type of excise tax applied R_excise_type
Tax structure: Uniform excise tax R_excise_uniform_varied
Average - taxes as a % of cigarette price - import duties R_imp_duty_average
Most sold brand of cigarettes - taxes as a % of price - import duties R_imp_duty_estimate
Average - taxes as a % of cigarette price - total tax R_total_tax_average
Most sold brand of cigarettes - taxes as a % of price - total tax R_total_tax_estimate
Congenital syphilis rate per 100 000 live births RateCS
Annual tax revenues - value added tax (vat) and other sales taxes Rev_VAT
Annual tax revenues - currency Rev_curr
Annual tax revenues - total excise (specific and ad valorem) Rev_excise
Annual tax revenues - total revenues Rev_govt_total
Annual tax revenues - import duties and all other taxes (excluding corporate taxes on tobacco companies) Rev_imp_other
Annual tax revenues - tobacco products included Rev_type
Annual tax revenues - year Rev_year
Alcohol, consumption of pure alcohol by type of beverage (%) SA_0000001398
Consumption by type of alcoholic beverage - market share (%) SA_0000001399
Alcohol, recorded per capita (15+) consumption (in litres of pure alcohol) SA_0000001400
Alcohol, recorded per capita (15+) consumption (in litres of pure alcohol), three-year average SA_0000001401
Alcohol, estimate of five-year change in recorded per capita (15+) consumption 2006-2010 SA_0000001402
Alcohol, total (recorded 3 year average + unrecorded) per capita (15+) consumption (in litres of pure alcohol) SA_0000001403
Alcohol, drinkers only (recorded 3 year average + unrecorded) per capita (15+)consumption in litres of pure alcohol SA_0000001404
Alcohol, tourist consumption (in litres of pure alcohol) SA_0000001405
Alcohol, unrecorded per capita (15+) consumption (in litres of pure alcohol) SA_0000001406
Alcohol, abstainers lifetime (%) SA_0000001409
Abstainers (15-19 years), lifetime (%) SA_0000001410
Alcohol, abstainers past 12 months (%) SA_0000001411
Abstainers (15-19 years), past 12 months (%) SA_0000001412
Alcohol, consumers past 12 months (%) SA_0000001413
Alcohol, former drinkers (%) SA_0000001414
Alcohol, heavy episodic drinking (population) past 30 days (%) SA_0000001415
Alcohol, heavy episodic drinking (drinkers only) past 30 days (%) SA_0000001416
Alcohol, patterns of drinking score SA_0000001417
Age-standardized DALYs, alcohol use disorders, per 100,000 SA_0000001418
Age-standardized DALYs, breast cancer, per 100,000 SA_0000001419
Age-standardized DALYs, colon and rectum cancers, per 100,000 SA_0000001420
Age-standardized DALYs, diabetes mellitus, per 100,000 SA_0000001421
Age-standardized DALYs, drownings, per 100,000 SA_0000001422
Age-standardized DALYs, falls, per 100,000 SA_0000001423
Age-standardized DALYs, fires, per 100,000 SA_0000001424
Age-standardized DALYs, ischaemic heart disease, per 100,000 SA_0000001425
Age-standardized DALYs, liver cancer, per 100,000 SA_0000001426
Age-standardized DALYs, liver cirrhosis, per 100,000 SA_0000001427
Age-standardized DALYs, maternal conditions, per 100,000 SA_0000001428
Age-standardized DALYs, mouth and oropharynx cancer, per 100,000 SA_0000001429
Age-standardized DALYs, oesophagus cancer, per 100,000 SA_0000001430
Age-standardized DALYs, poisoning, per 100,000 SA_0000001431
Age-standardized DALYs, prematurity and low birth rate, per 100,000 SA_0000001432
Age-standardized DALYs, road traffic accidents, per 100,000 SA_0000001433
Age-standardized DALYs, self-inflicted injury, per 100,000 SA_0000001434
Age-standardized DALYs, other unintentional injuries, per 100,000 SA_0000001435
Age-standardized DALYs, violence, per 100,000 SA_0000001436
Age-standardized death rates, alcohol use disorders, per 100,000 SA_0000001437
Age-standardized death rates, breast cancer, per 100,000 SA_0000001438
Age-standardized death rates, colon and rectum cancers, per 100,000 SA_0000001439
Age-standardized death rates, diabetes mellitus, per 100,000 SA_0000001440
Age-standardized death rates, drownings, per 100,000 SA_0000001441
Age-standardized death rates, falls, per 100,000 SA_0000001442
Age-standardized death rates, fires, per 100,000 SA_0000001443
Age-standardized death rates, ischaemic heart disease, per 100,000 SA_0000001444
Age-standardized death rates, liver cancer, per 100,000 SA_0000001445
Age-standardized death rates, liver cirrhosis, per 100,000 SA_0000001446
Age-standardized death rates, maternal conditions, per 100,000 SA_0000001447
Age-standardized death rates, mouth and oropharynx cancer, per 100,000 SA_0000001448
Age-standardized death rates, oesophagus cancer, per 100,000 SA_0000001449
Age-standardized death rates, poisoning, per 100,000 SA_0000001450
Age-standardized death rates, prematurity and low birth rate, per 100,000 SA_0000001451
Age-standardized death rates, road traffic accidents, per 100,000 SA_0000001452
Age-standardized death rates, self-inflicted injury, per 100,000 SA_0000001453
Age-standardized death rates, other unintentional injuries, per 100,000 SA_0000001454
Age-standardized death rates, violence, per 100,000 SA_0000001455
Age-standardized death rates (15+ years), alcoholic liver disease, per 100,000 SA_0000001456
Liver cirrhosis, age-standardized death rates (15+), per 100,000 population SA_0000001457
Age-standardized death rates (15+ years), poisoning, per 100,000 SA_0000001458
Road traffic crashes, age-standardized death rates (15+), per 100,000 population SA_0000001459
Age-standardized death rates (15+ years), violence, per 100,000 SA_0000001460
Alcohol dependence (15+ ), 12-month prevalence (%) with 95%CI SA_0000001461
Alcohol use disorders (15+), 12 month prevalence (%) with 95% SA_0000001462
Alcoholic psychosis, incidence, per 100,000 SA_0000001463
Cautions and arrests for drink-driving, per 100,000 population SA_0000001464
Hospital discharges, alcohol-related injuries and poisoning, per 100,000 SA_0000001465
Hospital discharges, alcoholic liver disease, per 100,000 SA_0000001466
Perceived trend in alcohol-related harm and consequences SA_0000001467
Treatment admissions (inpatient), alcohol dependence, per 100,000 SA_0000001468
Treatment admissions (inpatient), alcoholic psychosis, per 100,000 SA_0000001469
Alcohol-related road traffic crashes, per 100,000 population SA_0000001470
Alcohol-related road traffic crashes (% of all traffic crashes) SA_0000001471
Alcohol-related injury mortality, per 1,000 SA_0000001472
Alcohol-related disease mortality, per 100,000 (15+ years) SA_0000001473
Alcoholic excise tax revenue as a per cent of government revenue SA_0000001474
Annual revenues from alcohol excise tax in millions US$ SA_0000001475
Alcohol expenditure as a per cent of total household expenditure SA_0000001476
Social costs of alcohol use in millions US$ SA_0000001477
Adopted written national policy on alcohol SA_0000001502
Alcoholic beverage legally defined SA_0000001503
Alcohol use is banned SA_0000001504
Surrogate alcohol consumption is a problem SA_0000001505
National legislation to prevent illegal alcohol SA_0000001506
Advertising restrictions on national television SA_0000001507
Advertising restrictions on cable television SA_0000001508
Advertising restrictions on national radio SA_0000001509
Advertising restrictions on local radio SA_0000001510
Advertising restrictions in print media SA_0000001511
Advertising restrictions at cinemas SA_0000001512
Advertising restrictions on billboards SA_0000001513
Advertising restrictions at point-of-sale SA_0000001514
Advertising restrictions on the internet SA_0000001515
Restrictions on product placement on national television SA_0000001516
Restrictions on product placement on cable television SA_0000001517
Age limits on-premise service SA_0000001518
Minimum legal drinking age SA_0000001519
Legal blood alcohol concentration (BAC) limits SA_0000001520
Random breath testing (RBT) use SA_0000001521
Mandatory driver education for habitual offenders SA_0000001522
Prices for alcoholic beverages (average, US$) SA_0000001523
Trend in real price of alcoholic beverages relative to CPI over the past five years SA_0000001524
Off-premise sales restrictions on days SA_0000001525
Off-premise sales restrictions on hours SA_0000001526
Off-premise sales restrictions on places SA_0000001527
Off-premise sales restrictions on outlet density SA_0000001528
Off-premise sales restrictions at specific events SA_0000001529
Off-premise sales restrictions at petrol stations SA_0000001530
On-premise sales restrictions on days SA_0000001531
On-premise sales restrictions on hours SA_0000001532
On-premise sales restrictions on places SA_0000001533
On-premise sales restrictions on outlet density SA_0000001534
On-premise sales restrictions at specific events SA_0000001535
On-premise sales restrictions to intoxicated persons SA_0000001536
Restrictions on sponsorship of sporting events SA_0000001537
Restrictions on sponsorship of youth events SA_0000001538
Restrictions on sales promotion from producers (parties, events) SA_0000001539
Restrictions on sales promotion from retailers (sales below cost) SA_0000001540
Restrictions on sales promotion from owners of pubs and bars (alcohol for free) SA_0000001541
Government monopoly on production SA_0000001542
Government monopoly on retail sales SA_0000001543
Licence required for production SA_0000001544
Licence required for retail sales SA_0000001545
Excise tax as a per cent of the retail price of alcoholic beverages SA_0000001546
Excise duty (average) per hectolitre in Euros SA_0000001547
Excise tax as a per cent of the total retail price for 1 litre of pure alcohol SA_0000001548
Duty paid or excise stamp on alcohol container SA_0000001549
Excise tax on alcoholic beverages SA_0000001550
Value-added tax (VAT) on alcohol (%) SA_0000001551
Value-added tax (VAT), (%) SA_0000001552
Restrictions on alcohol use in public places SA_0000001553
Health warning labels on alcohol advertising SA_0000001554
Health warning labels on alcohol containers SA_0000001555
Awareness activities SA_0000001647
Information, education, prevention SA_0000001648
National drinking guidelines SA_0000001649
Standard drink measures, in grams per unit SA_0000001650
Monitoring SA_0000001651
Interventions, projects, training SA_0000001652
Treatment, services SA_0000001653
Surveys, research SA_0000001654
Counselling SA_0000001655
Production in 1000s hectolitres SA_0000001676
Imports in 1000s hectolitres SA_0000001677
Sales of beer in 1000s hectolitres SA_0000001678
Exports of beer (barley) in 1000s hectolitres SA_0000001679
Perceived trend in production SA_0000001680
Perceived trend in imports SA_0000001681
Perceived trend in sales SA_0000001682
Perceived trend in exports SA_0000001683
Sales of wine in 1000s hectolitres SA_0000001684
Sales of spirits in 1000s hectolitres SA_0000001685
Exports of wine (grape) in 1000s hectolitres SA_0000001686
Exports of spirits in 1000s hectolitres SA_0000001687
Projections for total (recorded + unrecorded) alcohol per capita (15+) consumption SA_0000001688
Age-standardized DALYs, cerebrovascular disease, per 100,000 SA_0000001689
Age-standardized death rates, cerebrovascular disease, per 100,000 SA_0000001690
Central coordinating entity for alcohol policy implementation SA_0000001691
Framework of national alcohol policy SA_0000001692
Level of adoption of national alcohol policy SA_0000001693
Sectors represented in national alcohol policy SA_0000001694
Cautions and arrests for public drunkenness, per 100,000 population SA_0000001695
Alcohol-related road traffic crashes with fatalities (% of all road traffic crashes with fatalities) SA_0000001696
Adopted written national policy on alcohol, year adopted SA_0000001697
Adopted written national policy on alcohol, year revised SA_0000001698
Age limits off-premise sales SA_0000001699
Consumer information on alcohol and health at points of sale SA_0000001700
Educational programmes involving target groups in school curriculum SA_0000001701
Brief interventions as health promotion/disease prevention SA_0000001702
Server training on a regular basis SA_0000001703
Data collection on alcohol-related health indicators SA_0000001704
System for monitoring alcohol-related harm SA_0000001705
National treatment policy for alcohol use disorders SA_0000001706
Persons with alcohol use disorders receiving treatment (%) SA_0000001707
Designation of alcohol tax revenues to health services SA_0000001708
National surveys on drink-driving SA_0000001709
Public-funded alcohol research/monitoring programmes SA_0000001710
Public funds designated for alcohol research/monitoring programmes, in Euros SA_0000001711
Community-based interventions/projects involving stakeholders SA_0000001712
Interventions/projects actively involving young people and civil society SA_0000001713
Training in screening and brief interventions for alcohol problems SA_0000001714
Counselling to children in families with alcohol problems SA_0000001715
Counselling to pregnant women with alcohol problems SA_0000001716
Prevention/counselling at workplaces for those with alcohol problems SA_0000001717
Action Plan for implementation of alcohol policy SA_0000001718
Advertising restrictions on social media SA_0000001719
Restrictions on product placement in films/movies SA_0000001720
Importance of measures for enhancing compliance with age limits SA_0000001721
Government support for community action SA_0000001722
Community-based interventions involving stakeholders SA_0000001723
National guidelines for implementing effective community-based interventions SA_0000001724
National alcohol policy specifically involves young people activities SA_0000001725
Penalties for drink driving SA_0000001726
Sobriety checkpoints SA_0000001727
Detection of marketing infringements SA_0000001728
Penalties for marketing infringements SA_0000001729
Price measures SA_0000001730
Level of taxation adjusted for inflation SA_0000001731
New types of alcoholic beverages emerging SA_0000001732
Consumer information about calories, additives, etc on containers SA_0000001733
Number of standard alcoholic drinks displayed on containers SA_0000001734
Alcohol content displayed on containers SA_0000001735
Action Plan for implementation of alcohol policy SA_0000001736
Alcohol, regional per capita (15+) consumption (in litres of pure alcohol) SA_0000001737
Regional alcohol per capita (15+) consumption- total SA_0000001738
Alcohol, heavy episodic drinking (population) past 30 days (%), age-standardized with 95%CI SA_0000001739
Alcohol-attributable Years of Life Lost (YLL) score SA_0000001740
Alcohol-attributable fractions (15+), liver cirrhosis deaths (%) SA_0000001741
Alcohol-attributable fractions (15+), road traffic crash deaths (%) SA_0000001742
Alcohol-attributable fractions, all-cause deaths (%) SA_0000001743
Alcohol, regional prevalence of alcohol dependence (%) SA_0000001744
Alcohol, regional prevalence of alcohol use disorders (%) SA_0000001745
Alcohol, total (recorded + unrecorded) per capita (15+) consumption with 95%CI, projections to 2025 SA_0000001746
Alcohol, recorded per capita (15+) consumption (in litres of pure alcohol), three-year average with 95%CI SA_0000001747
Alcohol, unrecorded per capita (15+) consumption (in litres of pure alcohol) with 95%CI SA_0000001748
Alcohol, total (recorded 3 year average + unrecorded) per capita (15+) consumption (in litres of pure alcohol) with 95%CI SA_0000001749
Average daily intake in grams of alcohol among drinkers SA_0000001750
Alcohol, average daily intake in grams among drinkers with 95%CI SA_0000001751
Alcohol, total (recorded + unrecorded) per capita (15+) consumption, projected estimates for 2012 SA_0000001752
Alcohol use disorders (15+), 12 month prevalence (%), age standardized, with 95%CI SA_0000001753
Alcohol, harmful use (15+), 12 month prevalence (%) with 95%CI SA_0000001754
15-19 years old heavy episodic drinkers (population), % with 95%CI SA_0000001755
15-19 years old heavy episodic drinkers (drinkers only), % SA_0000001756
15-19 years old abstainers, lifetime (%) SA_0000001757
15-19 years old former drinkers (%) SA_0000001758
15-19 years old, current drinkers (%) SA_0000001759
15-19 years old total alcohol consumption in litres of pure alcohol SA_0000001760
National guidelines for the prevention and reduction of alcohol-related harm in schools SA_0000001761
National guidelines for alcohol problem prevention and counselling at workplaces SA_0000001762
Workplace representatives nationally involved to prevent and address alcohol-related harm SA_0000001763
Server training SA_0000001764
Legal obligation for schools to include alcohol use prevention SA_0000001765
Legal obligation for schools to interact with parents regarding education and well-being SA_0000001766
Legislation on alcohol testing at workplaces SA_0000001767
Standard drink defined SA_0000001768
National sytems for monitoring alcohol consumption and harms SA_0000001769
Regular reports from national monitoring systems SA_0000001770
Comprehensive and regular reporting of alcohol situation SA_0000001771
Clinical guidelines for brief interventions SA_0000001772
National surveys on adult alcohol consumption SA_0000001773
National surveys on youth alcohol consumption SA_0000001774
National surveys on heavy espisodic drinking SA_0000001775
Data collection on Foetal Alcohol Syndome SA_0000001776
Data collected on harm from alcohol at workplace SA_0000001777
New types of alcoholic beverages emerging SA_0000001778
Level of enforcement of BAC limits SA_0000001779
15-years old any alcoholic beverage consumed at least once in lifetime, (%) SA_0000001780
15-years old any alcoholic beverage consumed in past 12 months, (%) SA_0000001781
15-years old first drink at 13 years or younger, (%) SA_0000001782
15-years old any alcoholic beverage consumed in past 30 days, (%) SA_0000001783
15-years old, any alcoholic beverage consumed at least once a week, (%) SA_0000001784
15-years old ever got drunk in the past 30 days, (%) SA_0000001785
13-15-years old any alcoholic beverage consumed in past 30 days, (%) SA_0000001786
13-15-years old first drink before age 14, (%) SA_0000001787
Alcohol-related road traffic crashes with fatalities, per 100,000 population SA_0000001788
Adolescent birth rate (births per 1 000 women aged 15-19) SDGABR
Mortality rate attributed to household and ambient air pollution (per 100 000 population) SDGAIRBOD
Age-standardized mortality rate attributed to household and ambient air pollution (per 100 000 population) SDGAIRBODA
Estimated direct deaths from major conflicts (per 100 000 population) SDGCONFLICT
Average death rate due to natural disasters (per 100 000 population) SDGDISASTER
Married or in-union women of reproductive age who have their need for family planning satisfied with modern methods (%) SDGFP
New HIV infections among adults 15-49 years old (per 1000 uninfected population) SDGHIV
Average of 13 International Health Regulations core capacity scores SDGIHR
Malaria incidence (per 1 000 population at risk) SDGMALARIA
Reported number of people requiring interventions against NTDs SDGNTDTREATMENT
Out-of-pocket expenditure as a percentage of total expenditure on health SDGOOP
Concentrations of fine particulate matter (PM2.5) SDGPM25
Mortality rate from unintentional poisoning (per 100 000 population) SDGPOISON
Proportion of population with primary reliance on clean fuels (%) SDGPOLLUTINGFUELS
Age-standardized road traffic mortality (per 100 000 population) SDGROADAGE
Proportion of births attended by skilled health personnel (%) SDGSAB
Skilled health professionals density (per 10 000 population) SDGSHP
Crude suicide rates (per 100 000 population) SDGSUICIDE
Age-standardized prevalence of current tobacco smoking among persons aged 15 years and older SDGTOBACCO
Mortality rate attributed to exposure to unsafe WASH services (per 100 000 population) SDGWSHBOD
Percentage of children under 15 years exposed to second-hand smoke SHS_1
Second-hand smoke attributable DALYs (’000) in children under 5 years SHS_10
Second-hand smoke attributable DALYs per 100’000 children under 5 years SHS_11
Percentage of women (15+ years) exposed to second-hand smoke SHS_2
Percentage of men (15+ years) exposed to second-hand smoke SHS_3
Second-hand smoke attributable deaths SHS_4
Second-hand smoke attributable DALYs (’000) SHS_5
Second-hand smoke attributable deaths per 100’000 capita SHS_6
Second-hand smoke attributable DALYs per 100’000 capita SHS_7
Second-hand smoke attributable deaths (’000) in children under 5 years SHS_8
Second-hand smoke attributable deaths per 100’000 children under 5 years SHS_9
Existence of sunbed regulations SUNBEDEXIST
Year of implementation of sunbed regulations SUNBEDEXISTYEAR
Access restrictions SUNBEDREG_ACCESS
Restriction and inspection of facilities SUNBEDREG_CONTROL
Information requirements SUNBEDREG_INFO
Safety requirements SUNBEDREG_SAFETY
Training requirements SUNBEDREG_TRAINING
Tuberculosis treatment coverage TB_1
Case detection rate for all forms of tuberculosis TB_8_c_cdr
New cases tested for RR-/MDR-TB (%) TB_c_dst_rlt_new_pct
Previously treated cases tested for RR-/MDR-TB (%) TB_c_dst_rlt_ret_pct
Laboratories providing tuberculosis diagnostic services using culture (per 5 million population) TB_c_lab_cul_5m
Laboratories providing drug susceptibility testing (DST) (per 5 million population) TB_c_lab_dst_5m
Laboratories providing tuberculosis diagnostic services using sputum smear microscopy (per 100 000 population) TB_c_lab_sm_100k
Treatment success rate for patients treated for MDR-TB (%) TB_c_mdr_tsr
Cases started on MDR-TB treatment TB_c_mdr_tx
Treatment success rate for new pulmonary smear-negative and extrapulmonary tuberculosis cases TB_c_new_snep_tsr
Treatment success rate: new TB cases TB_c_new_tsr
Tuberculosis - new and relapse cases TB_c_newinc
Total number of notified TB cases TB_c_notified
Treatment success rate: previously treated TB cases TB_c_ret_tsr
Treatment success rate: HIV-positive TB cases TB_c_tbhiv_tsr
Treatment success rate (new smear-positive cases) TB_c_tsr
Treatment success rate: XDR-TB cases TB_c_xdr_tsr
Confirmed cases of MDR-TB started treatment for MDR-TB (%) TB_conf_mdr_tx_pct
Number of incident tuberculosis cases TB_e_inc_num
Incidence of tuberculosis (per 100 000 population) (HIV-positive cases) TB_e_inc_tbhiv_100k
Number of incident tuberculosis cases, (HIV-positive cases) TB_e_inc_tbhiv_num
Estimated MDR-TB cases among notified pulmonary TB cases TB_e_mdr_num
Mortality of TB cases (all forms, excluding HIV) per 100 000 population TB_e_mort_exc_tbhiv_100k
Number of deaths due to tuberculosis, excluding HIV TB_e_mort_exc_tbhiv_num
Number of deaths from TB (all forms, excluding HIV) TB_e_mort_exc_tbhiv_num_save
Number of prevalent tuberculosis cases TB_e_prev_num
Estimated MDR/RR-TB cases among notified pulmonary TB cases TB_e_rr_in_notified_pulm
% of patients treated with fixed-dose combinations (FDCs) TB_fdc_pcnt
HIV-positive TB patients on ART (antiretroviral therapy) (%) TB_hiv_art_pct
HIV-positive TB patients on CPT (co-trimoxazole preventive therapy) (%) TB_hiv_cpt_pct
TB patients with known HIV status (%) TB_hivtest_pct
Tested TB patients HIV-positive (%) TB_hivtest_pos_pct
Confirmed cases of MDR-TB TB_mdr
New or unknown treatment history cases: Pulmonary, clinically diagnosed TB_new_clindx
New cases: extrapulmonary TB_new_ep
New or unknown treatment history cases: Pulmonary, bacteriologically confirmed TB_new_labconf
New cases: other TB_new_oth
New cases: pulmonary smear-negative TB_new_sn
New cases: Pulmonary, smear-negative/unknown/not done and other new cases TB_new_snsuoth
TB_new_snuoth TB_new_snuoth
New cases: Pulmonary, smear-positive TB_new_sp
New cases: pulmonary smear unknown/not done TB_new_su
Tuberculosis - new and relapse cases TB_newinc
Treatment history unknown TB_newret_oth
National Reference Laboratory (NRL) TB_nrl
Paediatric formulations procured for TB patients TB_paed_form
Rifampicin used throughout treatment TB_r_rgmn_new_initcont
Previously treated cases, excluding relapse TB_ret_nrel
Retreatment cases: other TB_ret_oth
Relapse cases (pre-2013 definition) TB_ret_rel
Relapse cases: Pulmonary, clinically diagnosed TB_ret_rel_clindx
Relapse cases: extrapulmonary TB_ret_rel_ep
Relapse cases: Pulmonary, bacteriologically confirmed TB_ret_rel_labconf
Retreatment cases: treatment after default (pulmonary smear and/or culture positive) TB_ret_tad
Retreatment cases: treatment after failure (pulmonary smear and/or culture positive) TB_ret_taf
Confirmed cases of RR-/MDR-TB TB_rr_mdr
Second-line drug susceptibility testing (DST) available TB_sldst_avail
Tuberculosis - new and relapse cases TB_tot_newrel
Monitor TOBACCO_0000000186
Protect from tobacco smoke TOBACCO_0000000187
Offer help to quit tobacco use TOBACCO_0000000188
Warn about the dangers of tobacco TOBACCO_0000000189
Enforce bans on tobacco advertising TOBACCO_0000000190
Raise taxes on tobacco TOBACCO_0000000191
Prevalence of smoking any tobacco product among persons aged >= 15 years TOBACCO_0000000192
Daily smoking of any tobacco product (age-standardized rate) TOBACCO_0000000193
Current smoking of cigarettes (age-standardized rate) TOBACCO_0000000194
Daily smoking of cigarettes (age-standardized rate) TOBACCO_0000000195
Health-care facilities (national legislation) TOBACCO_0000000196
Education facilities except universities (national legislation) TOBACCO_0000000197
Universities (national legislation) TOBACCO_0000000198
Government facilities (national legislation) TOBACCO_0000000199
Indoor offices (national legislation) TOBACCO_0000000200
Restaurants (national legislation) TOBACCO_0000000201
Pubs and bars (national legislation) TOBACCO_0000000202
Public transport (national legislation) TOBACCO_0000000203
All other indoor public places (national legislation) TOBACCO_0000000204
Number of places smoke-free (national legislation) TOBACCO_0000000205
Compliance with regulations on smoke-free environments (national legislation) TOBACCO_0000000206
Subnational smoke-free legislation authority exists TOBACCO_0000000207
Comprehensive bans in place subnationally TOBACCO_0000000208
Fines for violations TOBACCO_0000000209
Fines on the establishment TOBACCO_0000000210
Fines on the patron TOBACCO_0000000211
Dedicated funds for enforcement TOBACCO_0000000212
Citizen complaints and investigations TOBACCO_0000000213
Current smoking of any tobacco product (crude rate) TOBACCO_0000000337
Daily smoking of any tobacco product (crude rate) TOBACCO_0000000338
Current smoking of cigarettes (crude rate) TOBACCO_0000000339
Daily smoking of cigarettes (crude rate) TOBACCO_0000000340
Current users of any smokeless tobacco product (crude rate) TOBACCO_0000000341
Daily users of any smokeless tobacco product (crude rate) TOBACCO_0000000342
Ever users of any smokeless tobacco product (crude rate) TOBACCO_0000000343
Prevalence of current tobacco use among adolescents aged 13-15 years TOBACCO_0000000344
Current smokers of cigarettes (youth rate) TOBACCO_0000000345
Exposure to smoke at home TOBACCO_0000000346
Exposure to smoke outside home TOBACCO_0000000347
Jurisdiction name TOBACCO_0000000348
Number of people covered by subnational legislation TOBACCO_0000000349
Proportion of national population covered by subnational legislation TOBACCO_0000000350
Number of places smoke-free (subnational legislation) TOBACCO_0000000351
Health-care facilities (subnational legislation) TOBACCO_0000000352
Education facilities, except universities (subnational legislation) TOBACCO_0000000353
Universities (subnational legislation) TOBACCO_0000000354
Government facilities (subnational legislation) TOBACCO_0000000355
Indoor offices (subnational legislation) TOBACCO_0000000356
Restaurants (subnational legislation) TOBACCO_0000000357
Pubs and bars (subnational legislation) TOBACCO_0000000358
Public transport (subnational legislation) TOBACCO_0000000359
All other indoor public places (subnational legislation) TOBACCO_0000000360
Access to a toll-free quit line TOBACCO_0000000361
Smoking cessation support is available in hospitals TOBACCO_0000000362
Smoking cessation support is available in health clinics or other primary care facilities TOBACCO_0000000363
Smoking cessation support is available in offices of health professionals TOBACCO_0000000364
Smoking cessation support is available in the community TOBACCO_0000000365
Smoking cessation support is available in other settings TOBACCO_0000000366
Nicotine replacement therapy - legally sold TOBACCO_0000000367
Nicotine replacement therapy - place available TOBACCO_0000000368
Bupropion - legally sold TOBACCO_0000000369
Bupropion - place available TOBACCO_0000000370
Varenicline - legally sold TOBACCO_0000000371
Varenicline - place available TOBACCO_0000000372
Ban on deceitful terms on cigarette packaging TOBACCO_0000000373
Percentage of principal display area mandated to be covered by health warnings - front and back of cigarette packaging TOBACCO_0000000374
Percentage of principal display area mandated to be covered by health warnings - front of cigarette packaging TOBACCO_0000000375
Percentage of principal display area mandated to be covered by health warnings - back of cigarette packaging TOBACCO_0000000376
Specific health warnings are mandated for cigarette packaging TOBACCO_0000000377
Number of health warnings approved by the law for cigarette packaging TOBACCO_0000000378
Health warnings appear on each cigarette package and any outside packaging and labelling used in the retail sale TOBACCO_0000000379
Health warnings on cigarette packaging describe the harmful effects of tobacco use on health TOBACCO_0000000380
Font style, font size and colour of health warnings are mandated for cigarette packaging TOBACCO_0000000381
Health warnings on cigarette packaging must be rotated TOBACCO_0000000382
Health warnings on cigarette packaging must be written in the principal language(s) of the country TOBACCO_0000000383
Health warnings on cigarette packaging must include a photograph or graphic TOBACCO_0000000384
Ban on deceitful terms on other smoked tobacco packaging TOBACCO_0000000385
Percentage of principal display area mandated to be covered by health warnings - front and back of other smoked tobacco packaging TOBACCO_0000000386
Percentage of principal display area mandated to be covered by health warnings - front of other smoked tobacco packaging TOBACCO_0000000387
Specific health warnings are mandated for other smoked tobacco packaging TOBACCO_0000000388
Number of health warnings approved by the law for other smoked tobacco packaging TOBACCO_0000000389
Health warnings on other smoked tobacco packaging must be rotated TOBACCO_0000000390
Percentage of principal display area mandated to be covered by health warnings - back of other smoked tobacco packaging TOBACCO_0000000391
Health warnings appear on each other smoked tobacco package and any outside packaging and labelling used in the retail sale TOBACCO_0000000392
Health warnings on other smoked tobacco packaging describe the harmful effects of tobacco use on health TOBACCO_0000000393
Font style, font size and colour of health warnings are mandated for other smoked tobacco packaging TOBACCO_0000000394
Health warnings on other smoked tobacco packaging must be written in the principal language(s) of the country TOBACCO_0000000395
Health warnings on other smoked tobacco packaging must include a photograph or graphic TOBACCO_0000000396
Ban on deceitful terms on smokeless tobacco packaging TOBACCO_0000000397
Percentage of principal display area mandated to be covered by health warnings - front and back of smokeless tobacco packaging TOBACCO_0000000398
Percentage of principal display area mandated to be covered by health warnings - front of smokeless tobacco packaging TOBACCO_0000000399
Percentage of principal display area mandated to be covered by health warnings - back of smokeless tobacco packaging TOBACCO_0000000400
Specific health warnings are mandated for smokeless tobacco packaging TOBACCO_0000000401
Number of health warnings approved by the law for smokeless tobacco packaging TOBACCO_0000000402
Health warnings appear on each smokeless tobacco package and any outside packaging and labelling used in the retail sale TOBACCO_0000000403
Health warnings on smokeless tobacco packaging describe the harmful effects of tobacco use on health TOBACCO_0000000404
Font style, font size and colour of health warnings are mandated for smokeless tobacco packaging TOBACCO_0000000405
Health warnings on smokeless tobacco packaging must be rotated TOBACCO_0000000406
Most sold brand of bidis - price in US$ at official exchange rates TOBACCO_0000000407
Cheapest brand of bidis - currency reported TOBACCO_0000000408
Cheapest brand of bidis - price in currency reported TOBACCO_0000000409
Cheapest brand of bidis - price in US$ at official exchange rates TOBACCO_0000000410
Health warnings on smokeless tobacco packaging must be written in the principal language(s) of the country TOBACCO_0000000411
Health warnings on smokeless tobacco packaging must include a photograph or graphic TOBACCO_0000000412
Billboard and outdoor advertising TOBACCO_0000000413
International magazines and newspapers TOBACCO_0000000414
International television and radio TOBACCO_0000000415
Internet TOBACCO_0000000416
Local magazines and newspapers TOBACCO_0000000417
National television and radio TOBACCO_0000000418
Point of sale TOBACCO_0000000419
Subnational bans on tobacco advertising, promotion and sponsorship TOBACCO_0000000420
Compliance with bans on direct advertising TOBACCO_0000000421
Appearance of tobacco products in TV and/or films TOBACCO_0000000422
Brand name of non-tobacco products used for tobacco product TOBACCO_0000000423
Free distribution in mail or through other means TOBACCO_0000000424
Non-tobacco products identified with tobacco brand names TOBACCO_0000000425
Promotional discounts TOBACCO_0000000426
Sponsored events TOBACCO_0000000427
Compliance with bans on promotion and sponsorship TOBACCO_0000000428
Most sold brand of cigarettes - currency reported TOBACCO_0000000429
Most sold brand of cigarettes - price in currency reported TOBACCO_0000000430
Most sold brand of cigarettes - price in US$ at official exchange rates TOBACCO_0000000431
Cheapest brand of cigarettes - currency reported TOBACCO_0000000432
Cheapest brand of cigarettes - price in currency reported TOBACCO_0000000433
Cheapest brand of cigarettes - price in US$ at official exchange rates TOBACCO_0000000434
Most sold brand of bidis - currency reported TOBACCO_0000000435
Most sold brand of bidis - price in currency reported TOBACCO_0000000436
Most sold brand of cigarettes - taxes as a % of price - ad valorem excise TOBACCO_0000000437
Most sold brand of cigarettes - taxes as a % of price - import duties TOBACCO_0000000438
Most sold brand of cigarettes - taxes as a % of price - specific excise TOBACCO_0000000439
Most sold brand of cigarettes - taxes as a % of price - total tax TOBACCO_0000000440
Cheapest brand of cigarettes - taxes as a % of price - ad valorem excise TOBACCO_0000000441
Cheapest brand of cigarettes - taxes as a % of price - import duties TOBACCO_0000000442
Cheapest brand of cigarettes - taxes as a % of price - specific excise TOBACCO_0000000443
Cheapest brand of cigarettes - taxes as a % of price - total tax TOBACCO_0000000444
Most sold brand of bidis - taxes as a % of price - ad valorem excise TOBACCO_0000000445
Most sold brand of bidis - taxes as a % of price - import duties TOBACCO_0000000446
Most sold brand of bidis - taxes as a % of price - specific excise TOBACCO_0000000447
Most sold brand of bidis - taxes as a % of price - total tax TOBACCO_0000000448
Cheapest brand of bidis - taxes as a % of price - ad valorem excise TOBACCO_0000000449
Cheapest brand of bidis - taxes as a % of price - import duties TOBACCO_0000000450
Cheapest brand of bidis - taxes as a % of price - specific excise TOBACCO_0000000451
Cheapest brand of bidis - taxes as a % of price - total tax TOBACCO_0000000452
Government objectives on tobacco control exist TOBACCO_0000000453
National agency for tobacco control exists TOBACCO_0000000454
Number of full-time equivalent staff in national agency TOBACCO_0000000455
Annual budget for tobacco control in currency reported TOBACCO_0000000456
Reported currency TOBACCO_0000000457
Annual budget for tobacco control in US$ at official exchange rate TOBACCO_0000000458
Budget year TOBACCO_0000000459
Year of survey of adults TOBACCO_0000000502
Representativeness of survey of adults TOBACCO_0000000503
Repeating interval for survey of adults (years) TOBACCO_0000000504
Year of survey of youth TOBACCO_0000000505
Representativeness of youth survey TOBACCO_0000000506
Repeating interval for survey of youth (years) TOBACCO_0000000507
Most sold brand of cigarettes - taxes as a % of price - value added tax TOBACCO_0000000508
Most sold brand of cigarettes - taxes as a % of price - other taxes TOBACCO_0000000509
Most sold brand of bidis - taxes as a % of price - value added tax TOBACCO_0000000524
Most sold brand of bidis - taxes as a % of price - other taxes TOBACCO_0000000525
Anti-tobacco mass media campaigns TOBACCO_0000000526
National tobacco control programmes TOBACCO_0000000527
Survey age range TOBACCO_0000000528
Law mandates that health warnings appear on tobacco packages TOBACCO_0000000529
Health warnings on cigarette packaging must be placed at the top of the principal display areas of the package TOBACCO_0000000530
Health warnings on cigarette packaging do not remove or diminish the liability of the tobacco industry TOBACCO_0000000531
Health warnings on cigarette packaging law applys to products whether manufactured domestically imported AND for duty-free sale TOBACCO_0000000532
Health warnings on cigarette packaging must not be obscured in any way including by required markings such as tax stamps TOBACCO_0000000533
Health warnings on cigarette packaging law requires or establishes fines for violations TOBACCO_0000000534
Cigarette packaging and labelling must not use figurative or other signs including colors or numbers as substitutes for prohibited misleading terms and descriptors TOBACCO_0000000535
Cigarette packaging and labelling must not use descriptors depicting flavours TOBACCO_0000000536
Cigarette packaging and labelling must not display quantitative information on emission yields (such as tar nicotine and carbon monoxide) including when used as part of a brand name or trademark TOBACCO_0000000537
The quit line number must appear on cigarette packaging or labelling TOBACCO_0000000538
Plain packaging of cigarettes is mandatory (ie. the use of logos colours brand images or promotional information on packaging other than brand names and product names displayed in a standard colour and font style is prohibited) TOBACCO_0000000539
Law mandates that health warnings appear on smokeless tobacco packages TOBACCO_0000000540
Health warnings on smokeless tobacco packaging must be placed at the top of the principal display areas of the package TOBACCO_0000000541
Health warnings on smokeless tobacco packaging do not remove or diminish the liability of the tobacco industry TOBACCO_0000000542
Health warnings on smokeless tobacco packaging law applys to products whether manufactured domestically imported AND for duty-free sale TOBACCO_0000000543
Health warnings on smokeless tobacco packaging must not be obscured in any way including by required markings such as tax stamps TOBACCO_0000000544
Health warnings on smokeless tobacco packaging law requires or establishes fines for violations TOBACCO_0000000545
Smokeless tobacco packaging and labelling must not use figurative or other signs including colors or numbers as substitutes for prohibited misleading terms and descriptors TOBACCO_0000000546
Smokeless tobacco packaging and labelling must not use descriptors depicting flavours TOBACCO_0000000547
Smokeless tobacco packaging and labelling must not display quantitative information on emission yields (such as tar nicotine and carbon monoxide) including when used as part of a brand name or trademark TOBACCO_0000000548
The quit line number must appear on smokeless tobacco packaging or labelling TOBACCO_0000000549
Plain packaging of smokeless tobacco products is mandatory (ie. the use of logos colours brand images or promotional information on packaging other than brand names and product names displayed in a standard colour and font style is prohibited) TOBACCO_0000000550
At least one national mass media campaign ran during the survey period TOBACCO_0000000551
Campaign was part of a comprehensive tobacco control programme TOBACCO_0000000552
Campaign was pre-tested TOBACCO_0000000553
Formative research was conducted TOBACCO_0000000554
Campaign utilized media planning TOBACCO_0000000555
Earned media/public relations were used to promote the campaign TOBACCO_0000000556
Process evaluation was employed to assess implementation TOBACCO_0000000557
Outcome evaluation was employed to assess effectiveness TOBACCO_0000000558
Ban on appearance of tobacco brands in TV and/or films (product placement) TOBACCO_0000000559
Most sold brand of cigarettes - price in international dollars TOBACCO_0000000560
Cheapest brand of cigarettes - price in international dollars TOBACCO_0000000561
Most sold brand of bidis - price in international dollars TOBACCO_0000000562
Tobacco excises increased over the survey period TOBACCO_0000000563
Deaths attributable to the environment TOTENV_1
Total environment attributable DALYs per 100’000 children under 5 years TOTENV_10
Deaths attributable to the environment in children under 5 years (%) TOTENV_11
DALYs attributable to the environment in children under 5 years (%) TOTENV_12
Age-standardized deaths attributable to the environment (per 100 000 population) TOTENV_2
Disability-adjusted life years (DALYs) attributable to the environment TOTENV_3
Age-standardized DALYs attributable to the environment (per 100 000 population) TOTENV_4
Deaths attributable to the environment (%) TOTENV_5
Disability-adjusted life years (DALYs) attributable to the environment (%) TOTENV_6
Total environment attributable deaths (’000) in children under 5 years TOTENV_7
Total environment attributable deaths per 100’000 children under 5 years TOTENV_8
Total environment attributable DALYs (’000) in children under 5 years TOTENV_9
UV radiation UV_1
UV radiation attributable deaths UV_2
UV radiation attributable DALYs (’000) UV_3
UV radiation attributable deaths per 100’000 capita UV_4
UV radiation attributable DALYs per 100’000 capita UV_5
Bullied, past 30 days (%) VIOLENCE_BULLIED
Lifetime prevalence of child emotional abuse (%) VIOLENCE_CHILD_EMOTIONAL
Lifetime prevalence of child physical neglect (%) VIOLENCE_CHILD_NEGLECT
Lifetime prevalence of child physical abuse (%) VIOLENCE_CHILD_PHYSICAL
Lifetime prevalence of child sexual abuse (%) VIOLENCE_CHILD_SEXUAL
Extent of implementation of mental health services for victims of all types of violence VIOLENCE_EXTENTIMP_ALLTYPES
Child maltreatment: Extent of implementation of home-visiting programmes VIOLENCE_EXTENTIMP_CHILDHOMEVISIT
Extent of implementation of child protection services VIOLENCE_EXTENTIMP_CHILDPROTECTION
Elder abuse: Extent of implementation of caregiver-support programmes VIOLENCE_EXTENTIMP_ELDERCAREGIVER
Intimate partner violence: Extent of implementation of dating violence prevention programmes VIOLENCE_EXTENTIMP_PARTNERVIOLPREVENTION
Extent of implementation of medico-legal services for victims of sexual violence VIOLENCE_EXTENTIMP_VICTIMSMEDICOLEGAL
Youth violence: Extent of implementation of life-skills and social development programmes VIOLENCE_EXTENTIMP_YOUTHLIFESKILLS
Estimates of number of homicides VIOLENCE_HOMICIDENUM
Estimates of rates of homicides per 100 000 population VIOLENCE_HOMICIDERATE
Physical fighting, past 12 months (%) VIOLENCE_PHYSICAL_FIGHTING
Anti-tobacco mass media campaigns W-MM_Group
Do the health warnings on cigarette packaging include a photograph or graphic? W10_graphic_A
Do the health warnings on other smoked tobacco packaging include a photograph or graphic? W10_graphic_B
Do the health warnings on smokeless tobacco packaging include a photograph or graphic? W10_graphic_C
Do health warnings appear on each cigarette package and any outside packaging and labelling used in the retail sale? W11_outside_pack_A
Do health warnings appear on each other smoked tobacco package and any outside packaging and labelling used in the retail sale? W11_outside_pack_B
Do health warnings appear on each smokeless tobacco package and any outside packaging and labelling used in the retail sale? W11_outside_pack_C
Health warnings on cigarette packaging law applys to products whether manufactured domestically imported AND for duty-free sale W12_imports_dutyfree_A
Health warnings on other smoked tobacco packaging law applys to products whether manufactured domestically imported AND for duty-free sale W12_imports_dutyfree_B
Health warnings on smokeless tobacco packaging law applys to products whether manufactured domestically imported AND for duty-free sale W12_imports_dutyfree_C
Health warnings on cigarette packaging do not remove or diminish the liability of the tobacco industry W13_ind_liability_A
Health warnings on other smoked tobacco packaging do not remove or diminish the liability of the tobacco industry W13_ind_liability_B
Health warnings on smokeless tobacco packaging do not remove or diminish the liability of the tobacco industry W13_ind_liability_C
Do health warnings on cigarette packaging describe the harmful effects of tobacco use on health? W14_harm_effects_A
Do health warnings on other smoked tobacco packaging describe the harmful effects of tobacco use on health? W14_harm_effects_B
Do health warnings on smokeless tobacco packaging describe the harmful effects of tobacco use on health? W14_harm_effects_C
Does the law mandate specific health warnings on cigarette packaging? W15_specific_hw_A
Does the law mandate specific health warnings on other smoked tobacco packaging? W15_specific_hw_B
Does the law mandate specific health warnings on smokeless tobacco packaging? W15_specific_hw_C
How many health warnings are approved by the law for cigarette packaging? W16_number_hw_A
How many health warnings are approved by the law for other smoked tobacco packaging? W16_number_hw_B
How many health warnings are approved by the law for smokeless tobacco packaging? W16_number_hw_C
Health warnings on cigarette packaging law requires or establishes fines for violations W17_fines_A
Health warnings on other smoked tobacco packaging law requires or establishes fines for violations W17_fines_B
Health warnings on smokeless tobacco packaging law requires or establishes fines for violations W17_fines_C
Ban on deceitful terms on cigarette packaging W18_misleading_terms_A
Ban on deceitful terms on other smoked tobacco packaging W18_misleading_terms_B
Ban on deceitful terms on smokeless tobacco packaging W18_misleading_terms_C
Other smoked tobacco packaging and labelling must not use figurative or other signs including colors or numbers as substitutes for prohibited misleading terms and descriptors W19_Bolours_numbers_B
Cigarette packaging and labelling must not use figurative or other signs including colors or numbers as substitutes for prohibited misleading terms and descriptors W19_colours_numbers_A
Other smoked tobacco packaging and labelling must not use figurative or other signs including colors or numbers as substitutes for prohibited misleading terms and descriptors W19_colours_numbers_B
Smokeless tobacco packaging and labelling must not use figurative or other signs including colors or numbers as substitutes for prohibited misleading terms and descriptors W19_colours_numbers_C
Law mandates that health warnings appear on tobacco packages W1_HW_law_A
Law mandates that health warnings appear on other smoked tobacco packages W1_HW_law_B
Law mandates that health warnings appear on smokeless tobacco packages W1_HW_law_C
Cigarette packaging and labelling must not use descriptors depicting flavours W20_flavours_A
Other smoked tobacco packaging and labelling must not use descriptors depicting flavours W20_flavours_B
Smokeless tobacco packaging and labelling must not use descriptors depicting flavours W20_flavours_C
Cigarette packaging and labelling must not display quantitative information on emission yields (such as tar nicotine and carbon monoxide) including when used as part of a brand name or trademark W21_emissions_A
Other smoked tobacco packaging and labelling must not display quantitative information on emission yields (such as tar nicotine and carbon monoxide) including when used as part of a brand name or trademark W21_emissions_B
Other smoked tobacco packaging and labelling must not display quantitative information on emission yields (such as tar nicotine and carbon monoxide) including when used as part of a brand name or trademark W21_emissions_quant_B
Smokeless tobacco packaging and labelling must not display quantitative information on emission yields (such as tar nicotine and carbon monoxide) including when used as part of a brand name or trademark W21_emissions_quant_C
Cigarette packaging and labelling must display qualitative information on relevant constituents and emissions W22_emissions_qual_A
Other smoked tobacco packaging and labelling must display qualitative information on relevant constituents and emissions W22_emissions_qual_B
Smokeless tobacco packaging and labelling must display qualitative information on relevant constituents and emissions W22_emissions_qual_C
Cigarette packaging and labelling must display qualitative information on constituents and emissions on one or more of the principal display areas W23_emissions_front_back_A
Other smoked tobacco packaging and labelling must display qualitative information on constituents and emissions on one or more of the principal display areas W23_emissions_front_back_B
Smokeless tobacco packaging and labelling must display qualitative information on constituents and emissions on one or more of the principal display areas W23_emissions_front_back_C
Cigarette packaging and labelling must not display expiry dates W24_exp_date_A
Other smoked tobacco packaging and labelling must not display expiry dates W24_exp_date_B
Smokeless tobacco packaging and labelling must not display expiry dates W24_exp_date_C
The quit line number must appear on cigarette packaging or labelling W25_quitline_number_A
The quit line number must appear on other smoked tobacco packaging or labelling W25_quitline_number_B
The quit line number must appear on smokeless tobacco packaging or labelling W25_quitline_number_C
Plain packaging of cigarettes is mandatory (ie. the use of logos colours brand images or promotional information on packaging other than brand names and product names displayed in a standard colour and font style is prohibited). W26_plainSPACEpackaging_A
Plain packaging of smokeless tobacco products is mandatory (ie. the use of logos colours brand images or promotional information on packaging other than brand names and product names displayed in a standard colour and font style is prohibited). W26_plainSPACEpackaging_C
Plain packaging of cigarettes is mandatory (ie. the use of logos colours brand images or promotional information on packaging other than brand names and product names displayed in a standard colour and font style is prohibited). W26_plain_packaging_A
Plain packaging of other smoked tobacco products is mandatory (ie. the use of logos colours brand images or promotional information on packaging other than brand names and product names displayed in a standard colour and font style is prohibited). W26_plain_packaging_B
Plain packaging of smokeless tobacco products is mandatory (ie. the use of logos colours brand images or promotional information on packaging other than brand names and product names displayed in a standard colour and font style is prohibited). W26_plain_packaging_C
The sale of all smokeless tobacco products is completely banned W27_smokeless_prod_ban
Percentage of principal display area mandated to be covered by health warnings - front and back of cigarette packaging W2_pc_front_back_A
Percentage of principal display area mandated to be covered by health warnings - front and back of other smoked tobacco packaging W2_pc_front_back_B
Percentage of principal display area mandated to be covered by health warnings - front and back of smokeless tobacco packaging W2_pc_front_back_C
Percentage of principal display area mandated to be covered by health warnings - front of cigarette packaging W3_pc_front_A
Percentage of principal display area mandated to be covered by health warnings - front of other smoked tobacco packaging W3_pc_front_B
Percentage of principal display area mandated to be covered by health warnings - front of smokeless tobacco packaging W3_pc_front_C
Percentage of principal display area mandated to be covered by health warnings - back of cigarette packaging W4_pc_back_A
Percentage of principal display area mandated to be covered by health warnings - back of other smoked tobacco packaging W4_pc_back_B
Percentage of principal display area mandated to be covered by health warnings - back of smokeless tobacco packaging W4_pc_back_C
Health warnings on cigarette packaging must be placed at the top of the principal display areas of the package W5_top_side_A
Health warnings on other smoked tobacco packaging must be placed at the top of the principal display areas of the package W5_top_side_B
Health warnings on smokeless tobacco packaging must be placed at the top of the principal display areas of the package W5_top_side_C
Does the law mandate font style, font size and colour of health warnings on cigarette packaging? W6_font_A
Does the law mandate font style, font size and colour of health warnings on other smoked tobacco packaging? W6_font_B
Does the law mandate font style, font size and colour of health warnings on smokeless tobacco packaging? W6_font_C
Are the health warnings on cigarette packaging rotating? W7_rotation_A
Are the health warnings on other smoked tobacco packaging rotating? W7_rotation_B
Are the health warnings on smokeless tobacco packaging rotating? W7_rotation_C
Are the health warnings on cigarette packaging written in the principal language(s) of the country? W8_princ_langs_A
Are the health warnings on other smoked tobacco packaging written in the principal language(s) of the country? W8_princ_langs_B
Are the health warnings on smokeless tobacco packaging written in the principal language(s) of the country? W8_princ_langs_C
Health warnings on cigarette packaging must not be obscured in any way including by required markings such as tax stamps W9_no_obscure_A
Health warnings on other smoked tobacco packaging must not be obscured in any way including by required markings such as tax stamps W9_no_obscure_B
Health warnings on smokeless tobacco packaging must not be obscured in any way including by required markings such as tax stamps W9_no_obscure_C
Access to improved drinking water sources WAS_0000000001
Access to improved sanitation WAS_0000000002
Life expectancy at birth (years) WHOSIS_000001
Healthy life expectancy (HALE) at birth (years) WHOSIS_000002
Neonatal mortality rate (per 1000 live births) WHOSIS_000003
Adult mortality rate (probability of dying between 15 and 60 years per 1000 population) WHOSIS_000004
Low-birth-weight newborns (%) WHOSIS_000005
Infants exclusively breastfed for the first six months of life (%) WHOSIS_000006
Healthy life expectancy (HALE) at age 60 (years) WHOSIS_000007
Children aged <5 years underweight (%) WHOSIS_000008
Children aged <5 years overweight (%) WHOSIS_000009
Adults aged ≥ 20 years who are obese (%) WHOSIS_000010
Alcohol consumption among adults aged ≥ 15 years (litres of pure alcohol per person per year) WHOSIS_000011
Prevalence of smoking any tobacco product among adults (≥15 years) (%) WHOSIS_000012
Prevalence of current tobacco use among adolescents (13-15 years) (%) WHOSIS_000013
Stillbirth rate (per 1000 total births) WHOSIS_000014
Life expectancy at age 60 (years) WHOSIS_000015
Most recent census (year) WHS10_1
International Statistical Classification of Diseases and Related Health Problems (ICD) WHS10_10
Number of cause-of-death registration years available WHS10_2
Number of national population surveys - child anthropometry WHS10_3
Number of national population surveys - child mortality WHS10_4
Number of national population surveys - maternal mortality WHS10_5
Number of national population surveys - HIV prevalence WHS10_6
Number of national population surveys - adult health WHS10_7
Civil registration coverage of cause-of-death (%) WHS10_8
Ill-defined causes in cause-of-death registration (%) WHS10_9
Distribution of years of life lost by major cause group WHS2_126
Age-standardized mortality rate by cause (per 100 000 population) WHS2_131
Deaths due to HIV/AIDS (per 100 000 population) WHS2_138
Deaths due to malaria (per 100 000 population) WHS2_152
Distribution of causes of death among children aged <5 years (%) WHS2_155
Age-standardized mortality rate by cause (per 100 000 population) - Cancer WHS2_160
Age-standardized mortality rate by cause (per 100 000 population) - Cardiovascular WHS2_161
Age-standardized mortality rate by cause (per 100 000 population) - Injuries WHS2_162
Age-standardized mortality rate by cause (per 100 000 population) - Noncommunicable WHS2_163
Distribution of causes of death among children aged <5 years (%) - Malaria WHS2_164
Distribution of causes of death among children aged <5 years (%) - Pneumonia WHS2_165
Distribution of causes of death among children aged <5 years (%) - Injuries WHS2_166
Distribution of causes of death among children aged <5 years (%) - Diarrhoea WHS2_167
Distribution of causes of death among children aged <5 years (%) - Measles WHS2_168
Distribution of causes of death among children aged <5 years (%) - Causes arising in the perinatal period WHS2_169
Distribution of causes of death among children aged <5 years (%) - HIV/AIDS WHS2_170
Distribution of causes of death among children aged <5 years (%) - Other diseases WHS2_171
Distribution of years of life lost by broader causes (%) - Communicable WHS2_172
Distribution of years of life lost by broader causes (%) - Noncommunicable WHS2_173
Distribution of years of life lost by broader causes (%) - Injuries WHS2_174
Age-standardized mortality rate by cause (ages 30-70, per 100 000 population) - All causes WHS2_3070_all
Age-standardized mortality rate by cause (ages 30-70, per 100 000 population) - Cancer WHS2_3070_cancer
Age-standardized mortality rate by cause (ages 30-70, per 100 000 population) - Cardiovasular disease and diabetes WHS2_3070_cdd
Age-standardized mortality rate by cause (ages 30-70, per 100 000 population) - Chronic respiratory conditions WHS2_3070_chronic
Age-standardized mortality rate by cause (per 100 000 population) - Communicable WHS2_513
Distribution of causes of death among children aged <5 years (%) - Prematurity WHS2_514
Distribution of causes of death among children aged <5 years (%) - Neonatal sepsis WHS2_515
Distribution of causes of death among children aged <5 years (%) - Congenital anomalies WHS2_516
Distribution of causes of death among children aged <5 years (%) - Birth asphyxia WHS2_523
Cholera - number of reported cases WHS3_40
Diphtheria - number of reported cases WHS3_41
Japanese encephalitis - number of reported cases WHS3_42
Pertussis - number of reported cases WHS3_43
Leprosy - number of reported cases WHS3_45
Total tetanus - number of reported cases WHS3_46
Meningitis - number of reported cases WHS3_47
Malaria - number of reported confirmed cases WHS3_48
Poliomyelitis - number of reported cases WHS3_49
Yellow fever - number of reported cases WHS3_50
H5N1 influenza - number of reported cases WHS3_51
Plague - number of reported cases WHS3_52
Number of reported cases of tuberculosis WHS3_522
Mumps - number of reported cases WHS3_53
Number of reported cases of tuberculosis (DOTS) WHS3_54
Congenital Rubella Syndrome - number of reported cases WHS3_55
Neonatal tetanus - number of reported cases WHS3_56
Rubella - number of reported cases WHS3_57
Measles - number of reported cases WHS3_62
Diphtheria tetanus toxoid and pertussis (DTP3) immunization coverage among 1-year-olds (%) WHS4_100
Children aged <5 years with ARI symptoms taken to a health facility (%) WHS4_106
Children aged <5 years with diarrhoea receiving ORT (%) WHS4_107
Children aged <5 years with ARI symptoms who took antibiotic treatment (%) WHS4_108
Antenatal care coverage - at least one visit (%) WHS4_111
Antenatal care coverage - at least one visit, among girls aged 15-19 (%) WHS4_111_AGE1519
Births by caesarean section (%) WHS4_115
Hepatitis B (HepB3) immunization coverage among 1-year-olds (%) WHS4_117
Children aged 6-59 months who received vitamin A supplementation (%) WHS4_124
Neonates protected at birth against neonatal tetanus (PAB) (%) WHS4_128
Hib (Hib3) immunization coverage among 1-year-olds (%) WHS4_129
Antenatal care coverage - at least four visits (%) WHS4_154
Postnatal care visit within two days of birth (%) WHS4_2530
BCG immunization coverage among 1-year-olds (%) WHS4_543
Polio (Pol3) immunization coverage among 1-year-olds (%) WHS4_544
Antiretroviral therapy coverage among HIV-infected pregnant women for PMTCT (%) WHS4_99
Population using improved drinking-water sources (%) WHS5_122
Population using improved sanitation facilities (%) WHS5_158
Population using solid fuels (%) WHS5_512
Radiotherapy units (per 1 000 000 population) WHS6_100
Median availability of selected generic medicines (%) - Private WHS6_101
Hospital beds (per 10 000 population) WHS6_102
Median consumer price ratio of selected generic medicines - Private WHS6_116
Number of dentistry personnel WHS6_123
Physicians density (per 10 000 population) WHS6_125
Number of nursing and midwifery personnel WHS6_127
Number of physicians WHS6_136
Number of community health workers WHS6_140
Dentistry personnel density (per 10 000 population) WHS6_144
Nursing and midwifery personnel density (per 10 000 population) WHS6_148
Community health workers density (per 10 000 population) WHS6_150
Number of other health service providers WHS6_157
Other health service providers density (per 10 000 population) WHS6_159
Number of pharmaceutical personnel WHS6_517
Number of environment and public health workers WHS6_518
Density of pharmaceutical personnel (per 10 000 population) WHS6_519
Density of environment and public health workers (per 10 000 population) WHS6_520
Private prepaid plans as a percentage of private expenditure on health WHS7_103
Per capita government expenditure on health at average exchange rate (US$) WHS7_104
Per capita total expenditure on health (PPP int. $) WHS7_105
Per capita government expenditure on health (PPP int. $) WHS7_108
General government expenditure on health as a percentage of total government expenditure WHS7_113
External resources for health as a percentage of total expenditure on health WHS7_120
Social security expenditure on health as a percentage of general government expenditure on health WHS7_134
Out-of-pocket expenditure as a percentage of private expenditure on health WHS7_139
Total expenditure on health as a percentage of gross domestic product WHS7_143
Private expenditure on health as a percentage of total expenditure on health WHS7_147
General government expenditure on health as a percentage of total expenditure on health WHS7_149
Out-of-pocket expenditure as a percentage of total expenditure on health WHS7_150
Per capita total expenditure on health at average exchange rate (US$) WHS7_156
Measles (MCV) immunization coverage among 1-year-olds (%) WHS8_110
Literacy rate among adults aged >= 15 years (%) WHS9_85
Population (in thousands) total WHS9_86
Net primary school enrolment ratio (%) WHS9_87
Population median age (years) WHS9_88
Population proportion under 15 (%) WHS9_89
Population living on <$1 (PPP int. $) a day (%) WHS9_90
Civil registration coverage of births (%) WHS9_91
Population proportion over 60 (%) WHS9_92
Gross national income per capita (PPP int. $) WHS9_93
Civil registration coverage of causes of deaths (%) WHS9_94
Total fertility rate (per woman) WHS9_95
Population living in urban areas (%) WHS9_96
Annual population growth rate (%) WHS9_97
Crude birth rate (per 1000 population) WHS9_CBR
Crude death rate (per 1000 population) WHS9_CDR
Cellular subscribers (per 100 population) WHS9_CS
Preterm birth rate (per 100 live births) WHS_PBR
Water, sanitation and hygiene attributable deaths WSH_1
Water, sanitation and hygiene attributable deaths (’000) in children under 5 years WSH_2
Water, sanitation and hygiene attributable deaths per 100’000 capita WSH_3
Water, sanitation and hygiene attributable deaths per 100’000 children under 5 years WSH_4
Water, sanitation and hygiene attributable DALYs (’000) WSH_5
Water, sanitation and hygiene attributable DALYs (’000) in children under 5 years WSH_6
Water, sanitation and hygiene attributable DALYs per 100’000 capita WSH_7
Water, sanitation and hygiene attributable DALYs per 100’000 children under 5 years WSH_8
Warn about the dangers of tobacco W_Group
Antenatal care coverage - at least one visit (in the two or three years preceding the survey) (%) anc1
Antenatal care coverage - at least one visit (in the three years preceding the survey) (%) anc13
Antenatal care coverage - at least one visit (in the five years preceding the survey) (%) anc15
Antenatal care coverage - at least four visits (in the two or three years preceding the survey) (%) anc4
Antenatal care coverage - at least four visits (in the three years preceding the survey) (%) anc43
Antenatal care coverage - at least four visits (in the five years preceding the survey) (%) anc45
Adolescent fertility rate (per 1000 women aged 15-19 years) asfr1
BCG immunization coverage among one-year-olds (%) bcgv
Children aged < 5 years with pneumonia symptoms taken to a health facility (%) carep
Composite coverage index (%) cci
Child mortality rate (probability of dying between age 1 and age 5 per 1000 live births) cmr
Contraceptive prevalence - modern methods (%) cpmo
Contraceptive prevalence - modern and traditional methods (%) cpmt
Births by caesarean section (in the two or three years preceding the survey) (%) csection
Births by caesarean section (in the three years preceding the survey) (%) csection3
Births by caesarean section (in the five years preceding the survey) (%) csection5
DTP3 immunization coverage among one-year-olds (%) dptv
Early initiation of breastfeeding (in the two or three years preceding the survey) (%) ebreast
Early initiation of breastfeeding (in the three years preceding the survey) (%) ebreast3
Early initiation of breastfeeding (in the five years preceding the survey) (%) ebreast5
Family planning needs satisfied (%) famplan
Demand for family planning satisfied (%) fps
Full immunization coverage among 1-year-olds (%) full
Full immunization coverage among one-year-olds (%) fullv
Infant mortality rate (deaths per 1000 live births) imr
Children aged < 5 years sleeping under insecticide-treated nets (%) itnch
Children aged <5 years sleeping under insecticide-treated nets (%) itnchild
Pregnant women sleeping under insecticide-treated nets (%) itnpreg
Pregnant women sleeping under insecticide-treated nets (%) itnwm
Measles (MCV) immunization coverage among 1-year-olds (%) measlesv
Measles immunization coverage among one-year-olds (%) mslv
Neonatal mortality rate (deaths per 1000 live births) nmr
Prevalence of obesity in non-pregnant women aged 15 - 49 years, BMI >= 30 (%) obese
Prevalence of obesity in non-pregnant women aged 15-49 years, BMI >= 30 (%) obesewm
Children aged < 5 years with diarrhoea receiving oral rehydration salts (%) ors
Children aged < 5 years with diarrhoea receiving oral rehydration therapy and continued feeding (%) ort
Overweight prevalence in children aged <three years (%) overwgt3
Overweight prevalence in children aged <five years (%) overwgt5
Postnatal care visit within two days of birth (in the x years preceding the survey) (%) pncall
Postnatal care visit within two days of birth (in the three years preceding the survey) (%) pncall3
Postnatal care visit within two days of birth (in the five years preceding the survey) (%) pncall5
Postnatal care visit within two days of birth - born outside a health facility (in the x years preceding the survey) (%) pnchome
Postnatal care visit within two days of birth - born outside a health facility (in the three years preceding the survey) (%) pnchome3
Postnatal care visit within two days of birth - born outside a health facility (in the five years preceding the survey) (%) pnchome5
Children aged <5 years with ARI symptoms taken to facility (%) pneumcare
Postneonatal mortality rate (probability of dying between age 30 days and 11 months per 1000 live births) pnmr
Polio immunization coverage among one-year-olds (%) poliov
Births attended by skilled health personnel (in the two or three years preceding the survey) (%) sba
Births attended by skilled health personnel (in the three years preceding the survey) (%) sba3
Births attended by skilled health personnel (in the five years preceding the survey) (%) sba5
Children aged <5 years stunted (%) stunt
Stunting prevalence in children aged < 3 years (%) stunt3
Stunting prevalence in children aged < 5 years (%) stunt5
Total fertility rate (per woman) tfr
Under-five mortality rate (deaths per 1000 live births) u5mr
Children aged <5 years underweight (%) uweight
Underweight prevalence in children aged < 3 years (%) uweight3
Underweight prevalence in children aged < 5 years (%) uweight5
Children aged 6-59 months who received vitamin A supplementation (%) vita
Wasting prevalence in children aged < 3 years (%) wast3
Wasting prevalence in children aged < 5 years (%) wast5